Stockwinners Market Radar for May 05, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:01 EDT Avalara names Ee Lyn Khoo as Chief People Officer - Avalara "announced the appointment of human resources leader Ee Lyn Khoo as its new chief people officer."

18:53 EDT FDA limits authorized use of J&J's COVID vaccine - The U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine. "We recognize that the Janssen COVID-19 Vaccine still has a role in the current pandemic response in the United States and across the global community. Our action reflects our updated analysis of the risk of TTS following administration of this vaccine and limits the use of the vaccine to certain individuals," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research. "Today's action demonstrates the robustness of our safety surveillance systems and our commitment to ensuring that science and data guide our decisions. We've been closely monitoring the Janssen COVID-19 Vaccine and occurrence of TTS following its administration and have used updated information from our safety surveillance systems to revise the EUA. The agency will continue to monitor the safety of the Janssen COVID-19 Vaccine and all other vaccines, and as has been the case throughout the pandemic, will thoroughly evaluate new safety information." Janssen is owned by Johnson & Johnson. Reference Link

18:12 EDT Fluence Energy partners with Amazon.com for cloud computing services - Fluence Energy (FLNC) has tapped Amazon (AMZN) Web Services for cloud computing services to support Fluence's hardware and software platforms. This agreement builds on the broader collaboration amongst the companies, which includes providing Amazon with renewable energy to supports its goal to power its operations with 100% renewable energy by 2030. Fluence will leverage AWS cloud computing services to further develop its suite of digital applications for optimizing renewables and energy storage. Fluence will supply AES with energy storage solutions for some of the projects powering Amazon operations, and AES will deploy Fluence's IQ Bidding Application to optimize the value of some of their energy storage projects.

17:54 EDT Gladstone Commercial acquires industrial portfolio for $19.3M - Gladstone Commercial acquired a 260,719 square foot, two-property, industrial portfolio, with locations in Fort Payne, Alabama and Cleveland, Ohio, for a gross purchase price of $19.3M at a GAAP capitalization rate of 6.80%. The portfolio is 100% leased to Plasman with 11.4 years of remaining absolute NNN lease term. Plasman produces automotive bumpers, facias, grilles, and exterior trim components for major OEM brands, and is a significant player in the consumer goods market, specializing in precision molding. The acquisition of this industrial portfolio is consistent with Gladstone Commercial's growth strategy of acquiring functional assets leased to credit-worthy tenants.

17:50 EDT Lockheed Martin awarded $372.46M Navy contract modification - Lockheed Martin was awarded a $372.46M undefinitized firm-fixed-price modification to an order against a previously issued basic ordering agreement. This modification adds scope to procure F-35 Lightning II Lots 15-16 ancillary mission equipment requirements for the Air Force, Navy, and Marine Corps. Additionally, this modification adds scope to procure F-35 Lightning II initial spares for the Air Force, Navy, and Marine Corps, Foreign Military Sales, or FMS, customers, and non-U.S Department of Defense, or DOD, participants. Work is expected to be completed in December 2024. The Naval Air Systems Command is the contracting activity.

17:41 EDT Dropbox says will begin $1.2B buyback approved last quarter in Q2

17:40 EDT T2 Biosystems receives Nasdaq delisting notice - T2 Biosystems announced that on May 5, it received a letter from The Nasdaq Stock Market informing the company that its shares of common stock have failed to comply with the $1.00 minimum bid price required for continued listing on Nasdaq under Nasdaq Listing Rule 5450 and, as a result, the company's shares are subject to delisting. The letter further stated that the company may appeal the Nasdaq Staff delisting determination to a Nasdaq listing qualifications hearings panel.

17:31 EDT Dropbox CFO says 'committed' to long-term target of $1B in annual free cash flow - CFO Timothy Regan says: "We remain committed to our long-term objectives, including delivering operating margins of 30% to 32% and generating annual free cash flow of $1 billion by 2024. We also remain focused on allocating capital to growth initiatives, both organic as well as through acquisitions, while also returning a significant portion of our free cash flow to shareholders in the form of share repurchases." Comments taken from Q1 earnings conference call.

17:28 EDT Zillow Group falls over 9% to $35.27 after Q1 results, below-consensus guidance

17:21 EDT Post Holdings sees FY22 adjusted EBITDA $910M-$940M - Sees FY22 capital expenditures $250M-$300M. The company said, "Post management continues to expect fiscal year 2022 Adjusted EBITDA to be between $910-$940 million. This outlook incorporates known avian influenza incidents within Post's controlled network as of the date of this press release, including two incidents at Michael Foods' owned egg-laying facilities located in Wakefield and Bloomfield, Nebraska. This outlook does not incorporate significant expansion of avian influenza. Post management expects fiscal year 2022 capital expenditures to range between $250-$300 million. This includes approximately $40 million for the purchase of land and construction of a new facility with the intent to manufacture RTD shakes for BellRing."

17:17 EDT Block jumps 9% to over $104 after reporting Q1 results

17:13 EDT Apollo Medical CFO Eric Chin steps down, Chan Basho named interim CFO - Apollo Medical announced the appointment of Chan Basho to the newly created role of Chief Strategy Officer. Basho will also assume the position of interim CFO as Eric Chin has stepped down as CFO for personal reasons. Chin will continue to work with the company as an executive advisor to ensure a smooth transition. Basho possesses 15 years of experience in strategy, finance and operations at reputable healthcare companies, most recently having served as Vice President of Strategy and Corporate Development at Alignment Healthcare since 2018.

17:10 EDT Republic Services, Archaea Energy launch joint venture - Republic Services (RSG) and Archaea Energy (LFG) announced a joint venture to develop 39 RNG projects across the country. The partnership, the country's largest RNG portfolio build-out to date, will convert landfill gas into pipeline-quality RNG that can be used for a variety of applications to displace gas from fossil fuels. The initiative is expected to generate substantial progress towards Republic's long-term sustainability goal to beneficially reuse 50% more biogas by 2030. Archaea Energy will develop, engineer, construct and operate the RNG facilities, which will be located at Republic Services' landfills in 19 states. Construction is slated to begin on projects in late 2022, with completion and commissioning of the projects planned through 2027. When fully operational, the 39 projects are expected to generate more than 12.5 million MMBtu of RNG annually. The joint venture has signed a gas sale agreement with Republic to provide for the long-term ability to process landfill gas and sell RNG and related environmental attributes. Archaea Energy will contribute approximately $800M, and Republic will contribute approximately $300M for total investment of approximately $1.1B into the joint venture over the course of five years.

17:04 EDT Primoris awarded $120M solar project - Primoris Services announced a solar project with an estimated value of $120 million. The contract was secured by the Company's Energy/Renewables Segment. "Our Energy/Renewables team continues to execute at an exceptional level that brings clients back to us," said Tom McCormick, President and Chief Executive Officer of Primoris. "We value these strong and ongoing relationships." The award is for the engineering, procurement and construction of a utility-scale solar facility in the Southwest. Initial project construction will begin in the second quarter of 2022 with completion of the project expected in the first quarter of 2023.

16:58 EDT Teledyne FLIR awarded $500M U.S. Army contract - Teledyne FLIR Defense, part of Teledyne Technologies Incorporated, announced that it has won a five-year, firm-fixed-price, Indefinite Delivery/Indefinite Quantity contract worth up to $500.2M to provide advanced thermal imaging systems for the U.S. Army's Family of Weapons Sights-Individual program. Teledyne FLIR will produce the FWS-I at its facilities in Billerica, Massachusetts and Goleta, California. Maztech Industries, based in Irvine, California, will serve as subcontractor and system design lead.

16:52 EDT Splunk names Katie Bianchi as chief customer officer - Splunk announced the appointment of Katie Bianchi to Senior Vice President and Chief Customer Officer. Reporting to Gary Steele, Splunk President and CEO, and effective immediately, Bianchi will oversee Splunk's worldwide Customer Success and Professional Services team.

16:50 EDT Funko trading resumes

16:48 EDT Orion Engineered to build only acetylene-based additives plant in U.S. - Orion Engineered announced plans to build the only plant in the U.S. producing acetylene-based conductive additives - a critical link in the value chain for lithium-ion batteries, high-voltage cables and other products powering the global transition to electrification and renewable energy. Orion's planned facility in La Porte, Texas, south of Houston, will be backed by a long-term agreement for acetylene supplied from a neighboring site owned by Equistar Chemicals LP, a subsidiary of LyondellBasell. Orion will invest between $120 million to $140 million in the facility, expected to start up in the second half of 2024. This investment should increase the company's conductive additives capacity by approximately 12 kilotons per year. "With this investment, we will quadruple our effective manufacturing capacity of acetylene-based conductive additives," said Corning Painter, Orion's CEO. "We are already experiencing high demand for this material, so expanding capacity for it is one of our top investment priorities and a major milestone in our growth plans. This is a very big day for Orion."

16:46 EDT U.S. Xpress Enterprises says does not expect as 'favorable market backdrop' - The company states: "The Company does not expect as favorable of a market backdrop in the coming quarters as it has experienced in previous quarters but will remain focused on improving operational metrics which are within its control." CEO Eric Fuller: "I am pleased with our progress in the first quarter. However, looking ahead to the second quarter, we expect broader inflationary pressures to continue, which makes it critical to continue improving Variant's key metrics especially utilization and turnover. Sequential improvement in Variant's key metrics combined with overall fleet growth are key to improving our fixed cost coverage and demonstrating the operating leverage potential of our model. During the month of April, we saw Variant's turnover decline compared to the first quarter as well as improvement in Variant's safety statistics. Further progress on our remediation efforts will be apparent in Variant's key metrics as well as continued sequential overall fleet growth."

16:42 EDT Compass Diversified sees FY22 adjusted EBITDA $410M-$430M - As a result of the strong financial performance in the first quarter, as well as the expectations for the remainder of 2022, the Company is raising its guidance and expects its current subsidiaries, including Advanced Circuits, to produce consolidated Adjusted EBITDA the full calendar year of 2022 of between $410 million and $430 million. This estimate is based on the summation of our expectations for our current subsidiaries in 2022, absent additional acquisitions or divestitures, and excludes corporate expenses such as interest expense, management fees and corporate overhead. In addition, the Company expects to earn between $120 million and $135 million in Adjusted Earnings for the full year of 2022, excluding Advanced Circuits subsidiary results as this business has been classified as held for sale and is presented as discontinued operations.

16:39 EDT Insulet CEO Shacey Petrovic steps down - Insulet Corporation announced that Shacey Petrovic has decided to step down from her position as President and Chief Executive Officer (CEO) of Insulet for personal family reasons, effective June 1, 2022. Ms. Petrovic will continue to serve on the Company's Board of Directors. She will also serve as an advisor to the Company through May 2023 to support the leadership transition and Insulet's continued growth. Effective June 1, 2022, Jim Hollingshead, Ph.D. will succeed Ms. Petrovic as Insulet's President and CEO. Dr. Hollingshead has served as an independent member of Insulet's Board of Directors since 2019, and is currently President of the Sleep and Respiratory Care business at ResMed Inc.

16:36 EDT Foot Locker, Adidas announce new long-term strategic partnership - Adidas AG (ADDYY) and Foot Locker (FL) announced a new and enhanced partnership built around product innovation, elevated experiences, and deeper consumer connectivity. This enhanced relationship will establish Foot Locker as the lead partner for adidas in the basketball category, accelerate energy and hype launches, as well as include the development and expansion of key franchises across women's, kids, and apparel. Including all Foot Locker banners in North America, EMEA, and Asia-Pacific, the new strategic partnership will target over $2B in retail sales by 2025, nearly tripling levels from 2021. In 2022, adidas expects to generate incremental revenues of up to EUR 100M as a result of the new partnership. To execute the new plan, adidas will provide Foot Locker with a dedicated team to deliver an elevated consumer experience both in stores and online to help create demand and elevate the marketplace. This will involve partnership on product development, exclusive Foot Locker positioning, increased product allocations, shared marketing spend, and an elevated premium presence across Foot Locker's entire portfolio of banners with a special focus on key cities and communities that the companies jointly serve. Lastly, to provide consumers with a seamless consumer journey, on and offline, both partners will increase their digital focus and accelerate the rollout of the adidas partner program at Foot Locker.

16:29 EDT Northern Oil and Gas increases annual production guidance - Raises FY22 annual production view to 71,000 - 76,000 Boe per day from 70,000 - 75,000.

16:29 EDT Barings BDC announces increased quarterly dividend of 24c per share - Record date is June 8, with payment date of June 15.

16:28 EDT eBay part of consortium acquiring 12.5M Funko shares

16:26 EDT EOG Resources declares $1.80 per share special dividend - The Board of Directors declared a regular dividend of 75c per share on EOG's common stock. The regular dividend will be payable July 29, 2022, to stockholders of record as of July 15, 2022. The indicated annual rate is $3.00 per share. The Board of Directors also declared a special dividend of $1.80 per share on EOG's common stock. The special dividend will be payable June 30, 2022, to stockholders of record as of June 15, 2022. EOG also announced its commitment to return a minimum of 60% of free cash flow to shareholders each year. "This additional transparency complements the company's long-standing free cash flow priorities. It also reflects EOG's determination to continue to deliver on all its priorities, including returning additional cash to shareholders through special dividends or opportunistic share repurchases. The highest priority remains paying a sustainable and growing regular dividend. The $0.75 per share regular dividend declared today represents a $3.00 per share indicated annual rate. This is an 86% increase from the $1.61 per share regular dividends paid in 2021. EOG today also declared a special dividend of $1.80 per share. Combined with the $1.00 per share special dividend declared in February, EOG has committed to return $1.6 billion to shareholders through special dividends to-date in 2022," the company stated.

16:24 EDT Compass Minerals sees FY22 adjusted EBITDA $170M-$200M - Sees FY22 CapEx $100M-$110M.

16:19 EDT Standex announces new $100M share repurchase plan

16:18 EDT Block sees Square GPV up 29% for April - Block said: "We wanted to provide an update on the trends in our business during the month of April. For the second quarter of 2022, we believe three-year compound annual growth rates from 2019 through 2022 will help reflect underlying trends in each ecosystem, given the variability in year-over-year comparisons due to COVID-19. For the month of April, in aggregate, Square GPV is expected to be up 29% year over year. On a three-year CAGR basis, GPV growth is expected to be 24% in April, compared to 22% growth in the first quarter. In April, we expect Cash App gross profit, excluding Afterpay, to grow on a year-over-year and threeyear CAGR basis, driven by growth in monthly transacting actives, engagement across our ecosystem, and inflows into Cash App."

16:16 EDT Insulet sees Q2 revenue up 12%-15% - Consensus $295.4M

16:12 EDT Live Nation sees FY22 CapEx $375M

16:11 EDT Funko trading halted, news pending

16:09 EDT Atara Bio sees cash, equivalents sufficient to fund operations into 4Q23

16:08 EDT Air Transport Services sees 2022 capex of $590M - ATSG "continues to project a record $640 million in Adjusted EBITDA for 2022, up nearly $100 million from 2021. ATSG also projects 2022 capital spending of $590 million, including $200 million in sustaining capex and $390 million for growth, primarily funded by the strong Adjusted Free Cash Flow ATSG will generate this year."

16:03 EDT Vertex Pharmaceuticals still sees FY22 product revenues $8.4B-$8.6B - Sees FY22 adjusted effective tax rate 21%-22%.

15:42 EDT Akoya BioSciences trading resumes

15:25 EDT Boeing names Northern Virginia office as global headquarters - Boeing announced that its Arlington, Virginia campus just outside Washington, D.C. will serve as the company's global headquarters. "The aerospace and defense firm's employees in the region support various corporate functions and specialize in advanced airplane development and autonomous systems. In addition to designating Northern Virginia as its new headquarters, Boeing plans to develop a research & technology hub in the area to harness and attract engineering and technical capabilities," the company stated. Boeing will "maintain a significant presence at its Chicago location and surrounding region," the company added.

14:56 EDT SAI.TECH Global Corp trading halted, volatility trading pause

14:39 EDT Microsoft says 'Fortnite' to be available on Xbox Cloud Gaming - Microsoft (MSFT) announced that it has partnered with Epic Games to make "Fortnite" available on supported browser-enabled devices for free with Xbox Cloud Gaming in 26 countries. Starting Thursday, players only need a Microsoft account and an iOS, iPadOS, Android phone or tablet, or Windows PC with internet access to play "Fortnite" on the cloud. Investors in Epic Games include Tencent (TCEHY), KKR (KKR), Disney (DIS), and Sony (SONY). Reference Link

14:28 EDT Summer Game Fest to be broadcast in IMAX theaters - Summer Game Fest, a live-streamed video game announcement and presentation event, is partnering with IMAX for the June 9 event. The partnership will "bring all the amazing game trailers and announcements to you in the world's biggest and best cinema format." Tickets for the event will go on sale next week.

12:41 EDT Frontier pays $8.5M civil penalty to FTC over internet speed 'lying' - The Federal Trade Commission said it has moved to stop Frontier Communications "from lying to consumers and charging them for high-speed internet speeds it fails to deliver." Under a proposed order with the FTC and two California law enforcement agencies, Frontier "will be prohibited from tricking consumers about its slow internet service and required to support its speed claims," the agency said in a statement. Frontier must also provide current customers with "free and easy cancellations when it fails to deliver the promised speeds," it added. Frontier will be required to pay $8.5M in civil penalties and costs to the Los Angeles County and Riverside County District Attorneys' offices on behalf of California consumers as well as $250,000 that will be distributed to Frontier's California customers harmed by the company's practices. In addition, the company must discount the bills of California customers who have not been notified that they are receiving DSL service that is slower than the highest advertised speed. Frontier is required to deploy fiber-optic internet service to 60,000 residential locations in California over four years - at an estimated cost of $50M to $60M. Reference Link

12:06 EDT Athira says Glass Lewis recommends shareholders vote for director nominees - Athira Pharma announced that leading independent proxy advisory firm Glass, Lewis & Co. has recommended that shareholders vote "FOR" all three of Athira's director nominees - Joseph Edelman, John M. Fluke, Jr. and Grant Pickering - on the WHITE proxy card. In making its recommendations, Glass Lewis stated in its May 5, 2022, report: "Again, where Mr. Kayne's platform notionally asserts critical change is needed - in this case, with respect to sector expertise - it appears achievement of that change is ultimately subordinate to Mr. Kayne obtaining a board seat...analyses disclosed by both Athira and Mr. Kayne suggest the Company has outperformed noted benchmarks since [Mark Litton's] appointment [as CEO]...As such, we do not consider [Mr. Kayne's and Mr. Bickerstaff's] appointments necessarily portend significant, favorable change in this regard, and would, instead, express concern that their elections could be problematically destabilizing at a critical juncture for Athira despite what appear to be good faith efforts by the board to resolve the current contest...Much to the contrary, we are concerned the current campaign is disconcertingly titled (sic) toward offering overly favorable representations of Mr. Kayne's current business associate and the Company's former CEO, while providing investors with a very limited plan and a potentially compromised slate...In this case, having reviewed available arguments, we do not believe the Dissident has provided investors with suitable cause to conclude additional change to the Athira board is necessary at this time...Accordingly, we recommend shareholders use management's WHITE proxy card to vote FOR all nominees."

12:00 EDT Wayfair falls -19.3% - Wayfair is down -19.3%, or -$17.54 to $73.22.

12:00 EDT Direxion Daily Semiconductor Bear 3X Shares rises 12.8% - Direxion Daily Semiconductor Bear 3X Shares is up 12.8%, or $5.56 to $48.94.

12:00 EDT DHI Group rises 13.6% - DHI Group is up 13.6%, or 72c to $6.02.

11:31 EDT Kohl's, Walmart to pay $5.5M for alleged violations of Textile Act, FTC Act - The Department of Justice, together with the Federal Trade Commission, announced that Kohl's (KSS) and Walmart (WMT) have agreed to pay $2.5 million and $3 million in civil penalties, respectively, in as part of settlements to resolve allegations that Kohl's and Walmart violated the Textile Fiber Products Identification Act and associated rules and the Federal Trade Commission Act by making deceptive claims about products supposedly made of bamboo. In complaints filed in the U.S. District Court for the District of Columbia, the government alleged that since 2015, Kohl's and Walmart violated the Textile Act and Rules and the FTC Act by advertising products as made of bamboo when such products were actually made of rayon and did not contain bamboo fibers. The complaints also alleged that Walmart and Kohl's made deceptive claims that their products supposedly made of bamboo were environmentally friendly, and that Kohl's further claimed such products were produced free of harmful chemicals, when in fact rayon is produced using a chemical process that requires toxic chemicals and results in the emission of hazardous pollutants. Kohl's and Walmart did so even though, in 2010, both had received letters from the FTC warning them that improperly advertising products made of rayon as bamboo violated the Textile Rules and FTC Act. The stipulated orders require Kohl's to pay $2.5 million and Walmart to pay $3 million in civil penalties. The orders also bar Kohl's and Walmart from making misleading or unsubstantiated claims that products are made of bamboo or provide environmental benefits because they are derived from bamboo. More generally, the orders bar Kohl's and Walmart from advertising textiles comprised of manufactured fibers in a way that is false or deceptive as to their constituent fibers and requires them to satisfy ongoing record-keeping, certification and compliance obligations. Reference Link

11:03 EDT Crown Electrokinetics updates shareholders on manufacturing capacity - Crown Electrokinetics released a Shareholder Letter with an update on its new manufacturing facility and the availability of product for existing clients. The letter said, " One year ago, facing production delays due to reliance on contract manufacturers, we decided to vertically integrate all manufacturing into our own facilities located in Corvallis and Salem, Oregon. In addition to shortening our time to market, this operational decision would provide greater production control, improve our time to market, would likely result in enhanced margins, and would increase protection of Crown's intellectual property. Crown currently produces DynamicTint film on our prototype-production tool in our Corvallis facility. We can produce our film in this facility in limited quantities which has allowed us to test our production processes as well as to develop our Smart Windows Insert. Our prototype production line will produce 6-inch and 12-inch strips of our DynamicTint film for application in our first-generation Smart Window Insert. Initially, our Smart Windows Insert will be produced in a limited run to fulfill orders from our three current customers, Metro Spaces, Hudson Pacific and recently announced Brandywine Realty Trust. Collectively these three customers have a total of 281 buildings. With customer feedback on the performance, design, and usage of our first generation insert, we will develop our second-generation Smart Window Insert(TM) and we expect to transition to a new roll-to-roll production line capable of manufacturing film ranging from 12-inches up to 72-inches in width. We estimate that these significantly expanded manufacturing facilities could generate annualized revenue of between $110 - $120 million dollars, with an estimated EBITDA of approximately $20 million dollars. Changing manufacturing strategy initially required the addition of staff to perform key product and manufacturing design functions, supply chain logistics, assembly of our Smart Window Inserts, and the design and operation of our electrokinetic film production lines. As we near our commencement of production and assembly of our Smart Window Inserts, the needs of the Company shift from design and planning to manufacturing, assembly and delivery. As such, we are reorganizing our staffing to meet the needs of our production phase. As we transition from Research & Development to production, we have tapped Mr. Eddie Gordon to be Vice President of Operations. Eddie has been with the Company since July 2021 as the Senior Manufacturing Manager. His strong background in manufacturing and operations qualifies him to lead Crown's production of the generation 1.0 Smart Window Insert for delivery late summer 2022. Last week, Mr. Kai Sato, Crown's Chief Marketing Officer announced his intention to pursue personal opportunities. In addition to building and leading the Marketing department from its inception, Kai was instrumental over the past two years in helping define, shape, and instill Crown's culture, encompassing both our employees and our Board of Directors."

11:01 EDT Caterpillar acquires Tangent Energy Solutions - Caterpillar has acquired Tangent Energy Solutions, a U.S.-based energy-as-a-service company. Headquartered in Kennett Square, Pennsylvania, Tangent Energy provides customers with turnkey solutions for reducing energy costs, increasing energy efficiency, reducing emissions, monetizing electric grid support and providing resiliency for customer operations. "Tangent Energy has developed a suite of intelligent energy solutions that leverages advanced analytics to provide value to customers," said Jason Kaiser, vice president of Caterpillar Electric Power. Tangent Energy Solutions will continue to offer services under the Tangent Energy brand and operate under Caterpillar's Electric Power Division. Financial terms of the deal have not been disclosed.

10:57 EDT Bally's Chicago selected as preferred bidder for city's casino - Bally's Corporation announced that the City of Chicago has selected Bally's Chicago - a $1.7B destination casino, entertainment and hotel project - as the preferred bidder in the City's request for proposal process to construct and operate a world-class casino resort in downtown Chicago. Bally's worked cooperatively with city officials and community leaders throughout the RFP process to develop a project that embraced Chicago as a global gateway city, incorporating its vibrant cultural scene and highly diversified economy. The company said, "As evidenced in the City's evaluation report, Bally's Chicago provides the most economic value to it and its taxpayers, including an upfront payment of $40M and annual payments to the City totaling $4M. The project is expected to generate more than $800 million in stabilized gaming revenue on an annual basis - a substantial portion of which will support the City's obligations toward its fire and police union pensions. Additionally, Bally's Chicago will create more than 3,000 annual construction jobs and 3,000 permanent jobs upon completion of the project. Bally's has the financial resources to complete the project and will not require additional equity financing to fulfill its obligations." Bally's has entered into a neutrality agreement with the Chicago Federation of Labor and the company, which is already licensed by the Illinois Gaming Board, will work cooperatively and expeditiously with the IGB to obtain an operating license in Chicago.

10:47 EDT Adtran sees Q2 non-GAAP gross margin 35%-37%

10:42 EDT NetEase says 'will evaluate all strategic options' amid HFCAA addition - NetEase provided an update on its status under the Holding Foreign Companies Accountable Act. On May 4, the Securities and Exchange Commission provisionally named the company as a commission-identified issuer after the it filed its annual report, which included an audit report issued by a public accounting firm that the Public Company Accounting Oversight Board has determined that it is unable to inspect or investigate completely. NetEase said it has previously disclosed that its auditor, the independent registered public accounting firm that issued the audit report included in its annual report filed with the SEC, is currently not inspected by the PCAOB. In accordance with the HFCAA, if the SEC determines that a company has filed audit reports issued by a registered public accounting firm that cannot be inspected or investigated completely by the PCAOB for three consecutive years beginning in 2021, the SEC shall prohibit its shares or American depositary shares from being traded on a national securities exchange or in the over-the-counter trading market in the United States. NetEase said its shares continue to trade uninterrupted on the Nasdaq and that it "will continue to monitor market developments and evaluate all strategic options, with the appropriate counsel and guidance."

10:36 EDT Zeta Global down 14% after Bear Cave short report - Shares of Zeta Global are down $1.49, or 14%, to $8.91 after the company was called "a roll-up of low-quality marketing and data gathering companies" by The Bear Cave's Edwin Dorsey.

10:24 EDT CyberArk appoints Simon Mouyal as CMO - CyberArk announced the appointment of Simon Mouyal as Chief Marketing Officer. Mouyal will be responsible for overseeing global marketing strategy and execution at CyberArk to amplify brand awareness and further extend market leadership. Mouyal most recently served as CMO at athenahealth.

10:18 EDT Spirit Airlines: DOJ, courts wouldn't allow JetBlue deal

10:09 EDT Spirit Airlines sees Frontier deal closing by the end of year

10:07 EDT Amylyx Pharmaceuticals announces publication of CENTAUR trial analyses - Amylyx Pharmaceuticals announced the publication of long-term survival analyses of the Phase 2 CENTAUR trial adjusting for treatment crossover of the placebo group. The post hoc analyses suggested a larger survival benefit for AMX0035 when adjusting for placebo crossover ranging from 10.6 to 18.8 months compared with 6.9 months seen in the original prespecified intent-to-treat analysis in participants with amyotrophic lateral sclerosis, ALS. The final dataset compared time to death from the point of randomization in the Phase 2 CENTAUR trial through a cutoff date of July 20, 2020 and the date of the final open-label extension, OLE, phase participant visit. As of the July 2020 cutoff date, results of the final overall survival ITT analysis showed a significantly longer median survival duration of 6.9 months in those originally randomized to AMX0035 compared to those originally randomized to placebo. At the March 2021 cutoff date, results showed a significantly lower hazard of death and longer median survival duration of 4.8 months in those originally randomized to AMX0035 compared to those originally randomized to placebo. Results of the statistical methods that account for treatment crossover showed a greater survival benefit compared to ITT analysis. As of the July 2020 cutoff date, the observed median survival of 25.8 months in those originally randomized to AMX0035 compared to RPSFTM-adjusted median survival of 15.2 months in those originally randomized to placebo, a 10.6-month difference, with an HR of 0.39. The RPSFTM analysis models what the survival outcome from the placebo group would have been had participants not switched to AMX0035 in the OLE phase. At the March 2021 cutoff date, the same RPSFTM analyses were performed and yielded consistent results. As of the July 2020 cutoff date, post hoc assessment of subgroups based on randomization group as well as enrollment in the OLE phase demonstrated that participants who were originally randomized to AMX0035 and then enrolled in the OLE phase survived 18.8 months longer than participants who never received AMX0035.

10:04 EDT Banxa Holdings expands in new markets, launches USDC stablecoin partnership - BANXA Holdings announces key milestones reached to set up new local and/or cross border payment processing in Brazil and the broader LATAM market as well as the setup of local entities in Turkey the UK, and the USA. Banxa is also actively exploring the setup of operations in Luxembourg and India. The company is also announcing a first-to-market Web3 partnership with the enterprise blockchain Hedera, further cementing its commitment to creating more local on- and off-ramping infrastructure for people around the world. With an infrastructure that allows for higher fiat to crypto conversions than other providers in the market, Banxa's will now be able to offer end consumers even more local payment options beyond credit cards and includes instant bank transfers. Banxa is focused on growing these local entities over the coming months as well as acquisition of relevant licenses where required. The next phase of Banxa's global expansion plan will be to turn on local payments in each of these markets. The first of these has been in Brazil with the launch of PIX - the instant payment system provided by the Brazilian Central Bank. This now gives Banxa's global partner network access to millions more end customers with trusted local payment options. In emerging markets where credit card adoption is very low, Banxa's in market offering gives partners the ability to on-and off-ramp more customers with conversion rates up to three times higher than credit card only solutions. This is seen as critical for gaining mass adoption of crypto in developing markets like Brazil, Turkey and India.

10:01 EDT BAE Systems awarded $24M contract from DARPA - BAE Systems has received a $24M contract from the U.S. Defense Advanced Research Projects Agency to develop software that autonomously configures tactical networks for mission-critical communications as part of the Mission-Integrated Network Control program.

10:00 EDT Wayfair falls -20.0% - Wayfair is down -20.0%, or -$18.12 to $72.64.

10:00 EDT CoreCard rises 11.4% - CoreCard is up 11.4%, or $2.72 to $26.60.

10:00 EDT DHI Group rises 14.0% - DHI Group is up 14.0%, or 74c to $6.04.

09:58 EDT Kellogg has suspended shipments, investments into Russia

09:53 EDT Signify Health trading resumes

09:50 EDT Intercept reports Advanz to acquire Ocaliva rights outside U.S. for up to $450M - Earlier, Intercept Pharmaceuticals announced it has entered into an agreement to sell to Advanz Pharma, a pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe, certain foreign subsidiaries and rights regarding Intercept's international operations, including a license to commercialize Ocaliva outside of the U.S. "This agreement marks an important step forward for Intercept as the value it brings to our company allows us to significantly strengthen our balance sheet while providing us with greater strategic optionality during this transformational year and beyond," said Jerry Durso, President and Chief Executive Officer of Intercept. "We are committed to investing in our core focus areas in the U.S., including our PBC business, potential future activities in NASH, and our advancing and expanding pipeline. At the same time, we are confident that the strong international team will continue to build on our successful PBC business as they transition to Advanz Pharma." Upon closing of the transaction: Intercept will receive consideration in the amount of $405M upfront, subject to customary working capital and other adjustments. The company will receive an additional $45M from Advanz Pharma contingent upon receipt of an extension of pediatric orphan exclusivity in Europe. Intercept will receive royalties on any future net sales of obeticholic acid in NASH outside of the U.S., should Advanz Pharma pursue marketing authorization for this indication in ex-U.S. regions. Intercept will continue to be responsible for the manufacturing and supply of obeticholic acid globally and Advanz Pharma will be responsible for packaging, distribution and commercialization of the therapy in all markets outside of the U.S. The majority of Intercept employees outside of the U.S. will transfer to Advanz Pharma. The remaining international employees will continue to work for Intercept. Intercept will maintain an office in the UK to manage its global supply chain, support its quality organization, and support its global clinical trials.

09:48 EDT Kellogg sees Ukraine crisis impact on supply more weighted to 2H

09:47 EDT Kellogg 'largely' past strike impact, but still sees bottlenecks, shortages

09:47 EDT Wayfair falls -17.9% - Wayfair is down -17.9%, or -$16.26 to $74.50.

09:47 EDT Kellogg sees bottlenecks, shortages persisting at least through 1H - Comments taken from Q1 earnings conference call.

09:47 EDT Albemarle rises 9.7% - Albemarle is up 9.7%, or $20.83 to $236.30.

09:46 EDT AIkido Pharma reports Slinger Bag's filing for Nasdaq public listing - AIkido Pharma Inc. reported that, on March 30, 2022, Slinger Bag Inc. filed a Form S-1/A with the Securities and Exchange Commission requesting that the company's shares of common stock be publicly listed on the Nasdaq Capital Market under the symbol "CNXA." AIkido previously announced that it entered into an August 6, 2021, securities purchase agreement with Slinger Bag, which is the maker of The Slinger Bag, an advanced tennis ball shooter with a wheeled-bag design.

09:43 EDT Altamira Therapeutics receives regulatory approval to expand COVAMID trial - Altamira Therapeutics announced that it has received regulatory approval from the North Macedonia Ministry of Health to extend the COVAMID clinical investigation of its Bentrio nasal spray in patients with acute COVID-19 into the Republic of North Macedonia. North Macedonia is a sovereign nation, which borders Bulgaria to the west and has a population of 2.1 million. COVAMID is a randomized, placebo controlled clinical trial to evaluate the ability of Bentrio nasal spray to reduce the SARS-CoV-2 viral load in the nose, alleviate COVID-19 signs and symptoms, and decrease the frequency of COVID-19 related hospital admissions. In the COVAMID trial, 136 confirmed COVID-19 patients will be randomized at a 2:1:1 ratio to receive for 10 days either Bentrio, a placebo, or no treatment, followed by a 10-day observation phase. Last month, the Company announced that it had reached the midpoint for enrollment in its COVAMID clinical trial. Based on a blinded interim analysis to confirm the validity of statistical assumptions, Altamira will complete enrollment at 136 or expand to up to 180 subjects.

09:40 EDT Expion360 expands reseller network with battery marketer, distributor - Expion360 has begun distributing its products to the individual distributors of one of the largest and most well-established battery distribution networks in the U.S. These distributors sell millions of batteries annually through one of the nation's largest distribution networks, with more than 200 distribution centers providing Expion360 access to thousands of retail store locations nationwide, including major RV & Marine dealerships. Expion360 has already begun a strategic rollout of its lithium batteries and accessories to an initial 20 distribution locations in this large network, with the full rollout carefully scheduled over the next year to ensure timely deliveries and quality support.

09:37 EDT Peraso announces PRS1520 mmWave beamformer IC - Peraso announced its new PRS1520 mmWave beamformer integrated circuit. Combining a high level of integration with superior performance in a single device, the PRS1520 is anticipated to provide service providers with the opportunity to achieve a material reduction in their cost per subscriber. Furthermore, Peraso has implemented a scalable architecture that can be tailored to a host of mmWave-enabled, 5G devices, including customer premise equipment, laptops, tablets, and hotspots. Third party industry analysts are predicting annual volume of such equipment to be in the range of 42 million units in 2025, or an estimated TAM of $1.5 billion.

09:35 EDT Vimeo trading resumes

09:33 EDT Pond provides update to shareholders on AB Agri/Livalta project - Pond Technologies is providing an update on its agreement with Livalta, an AB Agri company, a subsidiary of Associated British Foods for the joint commercialization of algae-based animal feed ingredients. This global partnership between responsible protein specialists Livalta and Pond will produce commercial algae-based animal feed ingredients from CO2 emissions. Effectively, the technology is designed to take CO2 emissions out of the air to produce high value protein Details: In an agreement dated September 7, 2021, Livalta and Pond entered into an exclusive global partnership to grow algae-based animal feed from CO2 emissions. The engagement consists of two parts: a supply agreement, where AB Agri will purchase an algae demonstration system from Pond to be installed in the UK for the sum of approximately CAD$2.9 million and a license agreement, where Pond will receive up to CAD$2.6 million in technology access fees and an ongoing royalty based on the production from commercial algae plants deployed in the future. The demonstration system will be used to grow algae strains for animal feed trials and the development of commercial animal feeds which will be sold by AB Agri. The first product will be spirulina, combining 60% protein with essential vitamins and minerals. Spirulina is known for its nutritional and functional value both in food and animal feed. Livalta's pilot plant is currently anticipated to begin operating at British Sugar's Wissington site in Norfolk in Q4 2022. Since the start of the agreement Pond has received approximately $1.5 million CAD to date for initialization and milestone payments and has completed initial engineering work. Approximately $4 million CAD in license and engineering, procurement and construction payments remain to be earned by Pond. Additional project updates will be provided as Pond begins fabrication later this year. Spirulina are gaining increasing attention as a potentially game-changing animal feed ingredient. Until now, the technology to produce algae, at the scale, quality and cost required to be an affordable ingredient for animal feed, has remained elusive. This exclusive partnership, which brings together Pond's ground-breaking technology with Livalta's expertise in new proteins for animal feeds, is set to change that.

09:30 EDT Vimeo trading halted, volatility trading pause

09:27 EDT mPhase Technologies announces first auto dealer EV charging contract - mPhase Technologies (XDSL) announced that it has signed a purchase order with Shelly Electric for two 120KW level 3 DC fast chargers for a Pennsylvania-based Ford (F) dealership. The company said it is "excited to participate in the first phase of this charger installation, which is also expected to include level 2 chargers in the future." Like other major auto makers, Ford is in the process of transitioning its fleet to electric vehicles, which will require an increasing number of charging units on premises at dealerships. The mPhase installation will mark a number of firsts, including entry into the Pennsylvania market, the Company's initial level 3 charger sales, and the beginning of a targeted entry into the auto dealership vertical. "This purchase order checks some important boxes, most notably our ability to deliver a competitive offering in the important Level 3 category," said mPhase CEO and Chairman Anshu Bhatnagar. "Level 3 chargers are an essential part of the EV charging landscape, but even more important for high-powered vehicles such as the Ford F-150 Lightning and Mustang Mach-E. We expect the Level 3 charger will become a standard sight at dealerships for all car companies throughout the country as each fleet expands to include a higher percentage of EVs, particularly those with larger battery storage capacity. Our goal is to gain experience in this vertical in order to capture more business at dealerships in need of a reliable charging footprint."

09:21 EDT Wesana Health to conduct strategic review of care delivery division - Wesana Health Holdings is pleased to announce that following the completion of an initial tranche of its previously announced private placement, the Company has determined to move forward with a strategic review of Wesana's care delivery division. Strategic Rationale for Clinics and Other Care Delivery Asset Review: Feedback from the U.S. Food and Drug Administration validates the Company's strategic plan for simplification and growth. Given the clarity provided by FDA in the pre-IND meeting, and the Company's increased focus on drug development, Wesana has commenced a strategic review of the Company's assets with a focus on reviewing Wesana's care delivery division. The Company is reviewing strategic alternatives including, but not limited to, a sale of all the assets under the care delivery division, including: Wesana Clinics - a network of psychiatrist-led mental health clinics focused on serving the community through the delivery of personalized innovative psychiatric care, inclusive of ketamine therapy, medication management, psychotherapy, cognitive testing, and pharmacogenetic testing. Wesana Solutions - a medical-grade clinical SaaS platform focused on improving mental healthcare through facilitating access to leading edge clinical protocols and tracking their efficacy. In concert with EMRs and practice management systems, Wesana Solutions is intended to be used in clinics delivering psychedelics and related therapies, targeting the developing international psychiatric clinic and research market. PsyTech Connect - a leading community for the clinical use of psychedelics with over 8,000 actively engaged professionals.

09:21 EDT AB InBev says 'very pleased' with Q1 performance - Says underlying demand for premium products remains strong. Says grew volume in two thirds of markets in Q1. Says beer category "continues to demonstrate strength." Comments taken from Q1 earnings conference call.

09:20 EDT Core Scientific produced 1,121 bitcoins for its own account in April - Core Scientific announced production and operations updates for April 2022. "We expanded both our self-mining and hosting businesses in the month of April, producing 1,121 bitcoins for our own account and operating 8.1 EH/s for our hosting customers," said Mike Levitt, Core Scientific Chief Executive Officer. "Our team remains focused on operational excellence as we build our footprint to achieve our 2022 operating objectives." Core Scientific's self-mining operations produced 1,121 bitcoins in April, averaging 37.4 bitcoins per day, an increase from March's daily average of 36.9. As of April 30 the Company held 9,618 bitcoins produced from operations.

09:18 EDT CareCloud's talkEHR solution selected by UNMC - CareCloud announced that its talkEHR solution has been selected by the University of Nebraska Medical Center, UNMC, University Dental Associates, for its flexibility and scalability. CareCloud's Revenue Cycle Services and talkEHR are designed to help UNMC minimize downtimes and increase revenue. "Working with public universities requires a higher level of security, transparency, and administrative protections than is required by many other industries," said Al Nardi, SVP of Strategy at CareCloud. "By selecting our services and technology, UNMC has further validated CareCloud as a scalable solutions provider that meets workflow and system requirements set by public university systems."

09:16 EDT Harsco announces Stanton, president of Clean Earth division, left the company - Harsco announced that David Stanton has left the Company to pursue other opportunities after two years of service as president of its Clean Earth division. In the interim, Nick Grasberger, Chairman and Chief Executive Officer, Harsco Corporation, will assume the leadership of the Clean Earth business. He will be responsible for the daily management of the organization and its leadership team. He will be supported in this capacity by members of the Corporate Executive Leadership Team, all of whom will be taking more active daily roles in the running of the business. The Company plans to initiate a search for Stanton's successor at a future date.

09:14 EDT NextPlay Technologies completes acquisition of assets from FBP - NextPlay Technologies has completed the previously announced acquisitions of artificial intelligence game development and crypto asset management technologies that further enhance its digital business ecosystem for digital advertisers, consumers, and video gamers. The company acquired the assets, patents and video game development technology of Fighter Base Publishing along with its Make It Games brand. FBP's proprietary AI animation tools enable game or film characters to animate themselves, and be more lifelike in appearance and behavior, saving producers time and money over traditional animation. Fighter Base Publishing was founded by Mark Vange, who joined NextPlay as its chief technology officer in July of last year. Vange has authored more than 41 U.S. patents of breakthrough technologies, which have defined the video gaming industry. He earlier served as the chief technology officer of Electronic Arts Interactive following EAI's acquisition of a company he founded. NextPlay secured the new crypto technology through the acquisition of the assets of Token IQ, Inc., an early innovator in digital asset management and smart compliant token technology that was also founded by Vange. Token IQ's foundational IP employs a distributed ledger, like Ethereum or Stellar, to reconcile legal and regulatory requirements around digital assets, including Know Your Customer challenges, anti-money laundering and shareholder rights enforcement. These factors represent the most common pain points currently affecting the crypto markets. NextPlay plans to initially deploy the Token IQ technology through its NextBank International and Longroot Thailand subsidiaries, where it will be used to more effectively and securely serve our cryptocurrency customers. The technology is also available to license partners.

09:12 EDT Vacasa appoints John Banczak as chief strategy officer - Vacasa announced that senior VP of innovation John Banczak has been appointed chief strategy officer, a newly created role at the company. As CSO, Banczak will partner with the senior leadership team to develop the company's long-term growth plan and strategy toward reinventing the vacation rental industry through purpose-built technology to improve all aspects of the vacation rental experience. In addition, Banczak will lead its corporate development function, while continuing to run the innovation team and serve on Vacasa's senior leadership team.

09:11 EDT RCI Hospitality signs Bombshells agreement for Alabama - RCI Hospitality announced the signing of the second franchise development agreement for Bombshells Restaurant & Bar. Terms call for the opening of three locations over five years in Alabama, the first being in Huntsville. The agreement was signed with a newly formed entity established by hospitality entrepreneur Jerry Westlund of Nashville, who owns 30 nightclubs, bars and restaurants in 12 states, many of them in the South. RCI subsidiaries own 11 Bombshells in Texas with more under development. Sales for the 12-months ended in March 2022 totaled more than $60M. The first franchised location is expected to open soon in San Antonio.

09:10 EDT Rambus to acquire Hardent, terms undisclosed - Rambus announced it has signed an agreement to acquire Hardent, an electronic design company. This acquisition augments the team of engineers at Rambus and accelerates the development of CXL processing solutions for next-generation data centers. With 20 years of semiconductor experience, Hardent's silicon design, verification, compression, and Error Correction Code expertise provides resources for the Rambus CXL Memory Interconnect Initiative.

09:09 EDT WPP and Epic Games team to help agencies with 'digital experiences' for brands - WPP and Epic Games, the interactive entertainment company and developer of Fortnite and Unreal Engine, announced a new partnership to help WPP agencies deliver a new era of digital experiences for brands in the metaverse. The partnership will include a new training program to upskill thousands of WPP creatives and technologists on how to create custom brand experiences in Fortnite, and how to use Unreal Engine for real-time 3D creation and virtual production. This new metaverse curriculum will consist of three separate tracks for executives, creative practitioners, and media experts and strategists. Early to invest in the tools and talent needed to succeed in the metaverse, WPP believes that brands and creators have a tremendous opportunity to meet the need for connection and unlock unlimited creative potential within interactive virtual spaces. For brands embarking on this journey, success in the metaverse is dependent not only on creative excellence but deep production capabilities, sound strategies for amplifying digital experiences and expert knowledge of a complex online safety and privacy landscape. As a part of this partnership, WPP teams will work closely with experts at Epic to learn how to build next-generation interactive experiences leveraging Unreal Engine, an advanced real-time 3D creation tool used across a range of industries including games, film, architecture, fashion, automotive, music and live events. WPP teams will be able to take advantage of training and tools to create new experiences in Fortnite, where creators can build imaginative worlds for brands inside of one of the most globally popular online games. WPP has previously collaborated with SuperAwesome, an Epic Games company, to produce innovative work such as the immersive Island built for Adidas in Fortnite for its Ozweego sneaker line. WPP will also work with SuperAwesome to deepen its understanding of online safety and privacy to help its campaigns engage younger audiences safely.

09:09 EDT STMicroelectronics reveals advances global-shutter image sensor for DMSs - STMicroelectronics is enhancing vehicle safety with its latest global-shutter image sensors for driver monitoring systems, DMSs. DMSs continually watch the driver's head movements to recognize signs of drowsiness and distraction, enabling systems in the vehicle to generate warnings that can preserve the safety of occupants. "Drivers may not realize that they are unsafe to drive due to tiredness or distraction. DMS removes uncertainty by detecting the problem automatically, which protects all occupants as well as others traveling on the road," said Eric Aussedat, Executive Vice President, Imaging Sub-Group General Manager, STMicroelectronics. "Our latest global-shutter sensors deliver sensitivity and compactness, simplifying DMS hardware and reducing the overall system cost. This enables our customers and partners to deliver high-performing and reliable DMS systems reaching the legislation expectations." ST is supplying samples of its new sensor to lead customers now and mass production is scheduled for the beginning of 2023 for adoption in model year 2024 vehicles.

09:08 EDT Evofem announces 1-for-15 reverse stock split - Evofem approved a 1-for-15 reverse stock split of the company's common stock at the annual meeting of the Company held on May 4. The reverse stock split will take effect at the close of trading on the Nasdaq Capital Market, or 4:00 p.m. Eastern Time, on Thursday, May 5. The company's common stock will open for trading under a new CUSIP on the Nasdaq Capital Market on May 6, on a split-adjusted basis under the current ticker symbol "EVFM." The reverse stock split is intended to increase the per share trading price of the company's common stock to enable the company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The reverse split will reduce the number of shares of outstanding common stock from approximately 187,699,564 shares, the number of shares outstanding as of May 4, 2022, to approximately 12,513,304 shares. The company's CUSIP number will change to 30048L 203 as of 4:00 p.m., Eastern Time, on Thursday, May 5, 2022.

09:07 EDT Emcore awarded new contracts for flight stabilization, navigation IMUs - EMCORE announced that it has been awarded new contracts for the Booster Rate Gyro, BoRG, and Tri-Axial Inertial Measurement Unit, TAIMU, programs for space launch vehicles resulting from its acquisition of the L3Harris Space and Navigation business. The BoRG program award is a contract valued at over $12M for the production of IMUs used for flight stabilization of the booster stage of a multistage launch system.Pending successful demonstration of required capability and quality, EMCORE expects to be awarded follow-on production contracts for TAIMU within the next 12 months. "We are honored to supply our highest-grade inertial navigation equipment for these critical space launch vehicle programs," said Albert Lu, Senior Vice President and General Manager, Aerospace and Defense for EMCORE. "We look to further our close partnership with L3Harris through successful on-time deliveries for both the BoRG and TAIMU programs," added Lu.

09:06 EDT PDF Solutions' Cimetrix CIMControlFramework selected by Infinitesima - PDF Solutions announced that Infinitesima has selected the Cimetrix CIMControlFramework software to meet its demanding needs for precision equipment control and the data connectivity requirements of its Metron3D metrology system incorporating its innovative Rapid Probe Microscope technology. In order to mitigate the time-to-market risk associated with developing high quality software in its overall equipment development cycle, Infinitesima turned to PDF Solutions to ensure its innovative RPM system would include the data connectivity and control capabilities that the market and Infinitesima's customers require.

09:05 EDT Centene divests two pharmacy businesses for total proceeds of $2.8B - Centene has signed a definitive agreement to sell Magellan Rx to Prime Therapeutics and a separate definitive agreement to sell PANTHERx Rare to a consortium of The Vistria Group, General Atlantic, and Nautic Partners. Subject to customary purchase price adjustments, Centene expects to receive aggregate proceeds of approximately $2.8B from the transactions. Magellan Rx is a comprehensive pharmacy solutions organization with capabilities in specialty drug management, Medicaid administration, and comprehensive pharmacy benefits management. Centene acquired Magellan Rx in January 2022 as part of its acquisition of Magellan Health. The sale of Magellan Rx is subject to U.S. federal antitrust clearance, receipt of applicable regulatory approvals and satisfaction of other customary closing conditions and is expected to close in Q4. PANTHERx is a specialty and rare pharmacy. Centene acquired PANTHERx in December 2020. The sale of PANTHERx is subject to U.S. federal antitrust clearance, receipt of applicable regulatory approvals and satisfaction of other customary closing conditions and is expected to close in the next two to four months. Centene intends to use the majority of the net proceeds from the sales to repurchase stock and the balance to reduce debt. Each of the transactions is expected to be neutral to slightly accretive to Centene's Adjusted EPS in the 12-month period post-closing.

09:03 EDT Walgreens Boots Alliance reaches opioid settlement with State of Florida - Walgreens announced that it has entered into an agreement with the State of Florida to resolve all claims related to the distribution and dispensing of prescription opioid medications across the company's pharmacies in the state. The settlement amount of $683M includes $620M to be paid out to the State of Florida over 18 years, as well as a one-time payment of $63M for attorneys' fees. The settlement includes no admission of wrongdoing or liability by Walgreens. "As the largest pharmacy chain in the state, we remain focused on and committed to being part of the solution, and believe this resolution is in the best interest of all parties involved and the communities we serve across Florida," said Danielle Gray, executive vice president and global chief legal officer, Walgreens Boots Alliance, Inc. "Our pharmacists are dedicated healthcare professionals who live and work in the communities they serve, and play a critical role in providing education and resources to help combat opioid misuse and abuse."

09:02 EDT Rohm adds seven new devices to PrestoMOS lineup - ROHM Semiconductor announced that they have added seven new devices, the R60xxVNx series, to the PrestoMOS lineup of 600V Super Junction MOSFETs which stand out for their class-leading low ON resistance and the industry's fastest reverse recovery time. The R60xxVNx series is optimized for power circuits in industrial equipment requiring high power, such as servers, EV charging, and base stations, as well as motor drives in white goods that are increasingly using inverters to meet the trend towards greater energy savings.

09:01 EDT Enlivex Therapeutics announces issuance of two US patents on Allocetra - Enlivex Therapeutics announced the issuance of U.S. Patent Nos. 11,304,976 and 11,318,163. Each patent provides Enlivex with added intellectual property protection in the United States until at least 2036 with respect to claims covering methods of treating sepsis with Allocetra. Oren Hershkovitz, PhD, CEO of Enlivex, stated, "These latest patents add important depth to the IP portfolio protecting our sepsis program, with one specifically covering the treatment of sepsis derived from pneumonia, urinary, or biliary tract infections. These are three important sepsis subtypes that we intend to evaluate in our Phase II trial of Allocetra(TM). As we continue to advance this trial and our other programs, we plan to pursue additional patents in key geographies around the world to help maximize the value of our pipeline."

09:00 EDT Orbit International's Electronics Group reports April bookings of $1.3M - Orbit International reported bookings of approximately $1,300,000 for the month of April 2022. Deliveries for certain of these orders have already commenced and are expected to continue through the first quarter of 2023. Mitchell Binder, President and CEO of Orbit International commented, "We are pleased to report that on the heels of a firm booking month in March 2022, our OEG bookings for April 2022 were approximately $1,300,000. These orders include approximately $400,000 in orders for displays used on a significant aircraft program. The same customer has indicated that an additional order for approximately $500,000 should be expected during the current second quarter. In addition, our newly acquired subsidiary, Simulator Product Solutions, received orders for approximately $450,000 during April 2022. SPS continues to bid on a significant number of opportunities, although it faces competition for many of these orders. It should be noted that timing uncertainty in the receipt of contracts from our prime contractors doing business with the U.S government is an inherent factor in our industry. Although we have been successful in the booking of orders to date in 2022, we are finding that certain orders that we were expecting in the current quarter have been delayed to the second half of 2022 for both the OEG and our Power Group. These orders are generally follow-on orders on existing programs that we have delivered on for several years, but several factors are causing delays on these awards coming from the Department of Defense including work restrictions related to the pandemic and a shifting of prioritization of certain contract awards from the DoD. As in the past, timing remains an uncertainty, but we expect these purchase orders to eventually be received. Nevertheless, with the acquisition of SPS, we continue to expect a firm year of operating results."

08:58 EDT Edible Garden announces listing on Nasdaq, pricing of $14.7M IPO - Edible Garden AG Incorporated announced the pricing of its initial public offering of 2,930,000 shares of its common stock and accompanying warrants to purchase up to 2,930,000 shares of common stock. Each share of common stock is being sold together with one warrant to purchase one share of common stock with an exercise price of $5.00 per share at a combined offering price of $5.00, for gross proceeds of approximately $14.7 million, before deducting underwriting discounts and offering expenses. In addition, Edible Garden has granted the underwriters a 45-day option to purchase up to an additional 439,500 shares of common stock and/or warrants to purchase 439,500 shares of common stock to cover over-allotments at the initial public offering price, less the underwriting discount. The shares of common stock and warrants are expected to begin trading on The Nasdaq Capital Market on May 5, 2022, under the symbols "EDBL" and "EDBLW," respectively. The offering is expected to close on May 9, 2022, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital, debt repayment, the construction and/or acquisition of existing greenhouses, organizational build out, transaction bonuses for its executive officers, completion of a packhouse at its New Jersey facility, and general corporate purposes. Maxim Group LLC is acting as the lead book-running manager and Joseph Gunnar & Co. is acting as the joint book-running manager in connection with the offering.

08:57 EDT Coherus Biosciences appoints Charlie Newton to board of directors - Coherus BioSciences announced the appointment of former investment banker and renowned biotech strategist Charlie Newton to its Board of Directors. Mr. Newton will also serve on the Audit Committee of the Board of Directors. Mr. Newton is the Chief Financial Officer of Lyell Immunopharma, a NASDAQ-listed biotechnology company.

08:54 EDT Patriot National reports Q1 EPS 20c vs 22c last year - Patriot President & CEO Robert Russell stated: "The Bank experienced strong earnings and asset generation in the first quarter of 2022. Additionally, margin expansion and continued improvement in nonperforming assets contributed to the outcome for the quarter. The Bank continues to focus on solid asset generation and its cost of funds as we navigate the current economic cycle."

08:52 EDT Wayfair says expects revenue growth to accelerate as year goes on - Says war and widespread inflation should weigh on consumer spending. Says revenue growth year-over-year to accelerate as year goes on. Says hard to pinpoint when things will normalize. Says massive market opportunity. Says not providing formal topline guidance. Sees Q2 gross margin 27%-28%. Sees Q2 operational expenses $55M-$565M. Sees Q2 adjusted EBITDA margin similar to Q1. Says macro environment is so murky right now. Says can not commit to saying it will be adjusted EBITDA profitable for the full year. Comments and guidance taken from Q1 earnings conference call.

08:50 EDT Tarsus Pharmaceuticals presents findings from Atlas Continuation study - Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, presented data from its Atlas Continuation study on the negative impact Demodex blepharitis has on daily life and visual function among certain patient groups, as well as preliminary findings from the Pandora study on coexisting bacterial burden for patients with Demodex blepharitis. Both studies were presented at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting. "This research reinforces the significant burden and clinical impact of Demodex blepharitis, particularly among the most commonly seen patients in eye care practices," said Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer of Tarsus. "We also recently announced strong, positive topline results from our second pivotal trial, Saturn-2, studying our lead investigational therapeutic, TP-03, for the treatment of Demodex blepharitis. With this positive data, we plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration later this year, which is exciting for eye care professionals and the millions of patients suffering from this disease without an effective treatment option. We are committed to advancing our path forward to bring a potential definitive standard of care to these patients in need."

08:48 EDT Smart for Life appoints Darren Minton as CEO - Smart for Life announced that it has named Darren Minton, the Company's current President, as Chief Executive Officer. The announcement was made by A.J. Cervantes, Jr., Smart for Life's Chairman. Mr. Minton has served as President since September 2017 and as a member of the board of directors since November 2018.

08:47 EDT ABVC BioPharma announces streamlined Vitargus manufacturing process - ABVC BioPharma announced that Vitargus, its gel-like substance that helps the eye maintain a round shape and keeps the retina in place during and after retinal re-attachment surgery, will be manufactured through a new aseptic process that enhances the stability, consistency and efficacy of the final product, while significantly reducing manufacturing time. This new manufacturing process eliminates the labor-intensive and time-consuming gamma ray sterilization of the Vitargus components by using a sterile fill-lyophilization-finish. Early clinical studies indicate that Vitargus has unique properties that eliminate the need for post-surgery patient face-down positioning, while significantly improving patient comfort and visual acuity during the surgical recovery period, as compared to current products available on the market. It is the first biodegradable vitreous substitute to eliminate the need for a second post-op surgery to remove surgical fluids. The upcoming Phase II study to be initiated in Australia and Thailand is expected to demonstrate the safety and effectiveness of Vitargus, compared to the commonly used SF6 Gas OE. The new streamlined manufacturing process has been successfully scaled up under cGMP conditions to ensure enough Vitargus can be economically produced for both Phase II, as well as subsequent Phase III clinical studies involving more than 175 patients.

08:45 EDT Brink's appoints Castillo president of North American operations - The Brink's Company (BCO) announced that Daniel Castillo will be named executive vice president and president of its North American operations. Mark Eubanks, Brink's chief operating officer, will work closely with Castillo to facilitate a seamless transition. Castillo will join the executive leadership team and report to Eubanks, who will become president and chief executive officer on May 6, as previously announced. Castillo will join Brink's in early June from JELD-WEN (JELD).

08:44 EDT Palisade Bio, Newsoara receive NMPA clearance for Phase 3 trial of LB1148 - Palisade Bio and co-development partner Newsoara Biopharma announced they have received clearance from the National Medical Products Administration in China to proceed with their Phase 3 clinical trial to evaluate LB1148 for accelerated return of bowel function in adult patients undergoing bowel/abdominal surgery. This comes shortly after the announcement of the Phase 3 protocol clearance by the U.S. Food and Drug Administration. LB1148 is an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. In a previously conducted Phase 2 trial in gastrointestinal surgery, Palisade Bio and Newsoara demonstrated LB1148 had a statistically significant effect in accelerating the return of bowel function in patients undergoing elective bowel resection surgery. Based on the strong efficacy profile in acceleration of the time to recover bowel function combined with a favorable safety and tolerability profile observed, Palisade Bio and Newsoara are advancing LB1148 to Phase 3 clinical trials in the United States and China for accelerating the return of bowel function for major surgical indications. The Phase 3 trial is designed as a multi-centered, randomized, double-blinded, parallel-group, placebo-controlled clinical trial, and will assess the safety and efficacy of LB1148. All patients enrolled in the trial will undergo a scheduled bowel resection surgery that will include either laparotomy or laparoscopic surgical approaches. As previously announced, LB1148 is being developed in China for return of postoperative bowel function and reduction of post-surgical adhesions. Under the terms of the existing agreement with the Company, Newsoara is responsible for fully funding the Phase 3 development in China and will be required to make milestone payments to Palisade Bio upon achievement of certain regulatory and, if approved, commercial milestones and tiered royalty payments on any future annual net sales of LB1148 in greater China.

08:43 EDT Alzamend Neuro begins Phase IIA MAD clinical trial for for AL001 for dementia - Alzamend Neuro announced that the first patient with mild to moderate Alzheimer's disease has been dosed in a 12-month Phase IIA multiple ascending dose study for dementia related to Alzheimer's. The MAD study is for the purpose of evaluating the safety and tolerability of AL001 under multiple-dose, steady-state conditions and determining the maximum tolerated dose in patients diagnosed with mild to moderate Alzheimer's. AL001 is a novel lithium-delivery system; it is a lithium-salicylate-L-proline engineered ionic cocrystal under development as an oral treatment for patients with dementia related to mild, moderate, and severe cognitive impairment associated with Alzheimer's. AL001 has the potential to deliver benefits of marketed lithium carbonate while mitigating or avoiding current toxicities associated with lithium. "Advancing AL001 into a Phase IIA clinical trial as planned marks an important milestone for Alzamend," said Stephan Jackman, Chief Executive Officer of Alzamend. "We are one step closer to proving that AL001 could potentially provide clinicians with a major improvement over current lithium-based treatments and may constitute a means of treating over 40 million Americans suffering from Alzheimer's and other neurodegenerative diseases and psychiatric disorders. We look forward to completing the MAD study and further advancing clinical development of this promising potential therapeutic."

08:43 EDT Focus Financial CFO says Q1 exceeded expectations 'on all measures' - "Our performance in the 2022 first quarter exceeded our expectations on all measures and reinforced the value of our disciplined execution and capital allocation. Our scale and the diversity of our global partnership were instrumental in helping us to deliver this level of performance. While the dynamics driving the current environment are different than what we experienced at the outset of the pandemic in 2020, our partner firms are equally well equipped to weather this storm and are generating excellent results. Similar to 2020, we are positioning ourselves to take advantage of the opportunities that will arise post crisis. I have no doubt that we will navigate the current challenges and our business will emerge even stronger and better positioned for growth," said Focus Financial CFO Jim Shanahan.

08:41 EDT AcuityAds announces TSX acceptance of normal course issuer bid - AcuityAds Holdings announced that it has received approval from the Toronto Stock Exchange to proceed with a normal course issuer bid. Under the NCIB, the Company may purchase for cancellation up to 5,500,000 common shares of the Company. Daily purchases will be limited to 140,680 Shares, other than block purchase exceptions. As at May 3, 2022, AcuityAds had 60,926,530 Shares issued and outstanding. The maximum number of Shares that may be purchased under the NCIB represents approximately 9.95% of AcuityAds' public float as at May 3, 2022. The NCIB will commence on May 16, 2022 and may continue to May 15, 2023 or such earlier time as the NCIB is completed or terminated at the option of the Company. The Shares will be purchased on behalf of the Company by a registered broker through the facilities of the TSX and through other alternative Canadian trading platforms at the prevailing market price at the time of such transaction. In connection with the NCIB, subject to approval of the TSX, AcuityAds intends on entering into an automatic share purchase plan with its designated broker to allow for the purchase of Shares under the NCIB at times when AcuityAds normally would not be active in the market due to internal trading black-out periods. Such purchases will be determined by the broker at its sole discretion, based on the purchasing parameters set out by the Company in accordance with the rules of the TSX, applicable securities laws and the terms of the ASPP. Purchases of Shares under the ASPP may be made through the facilities of the TSX and alternative Canadian trading systems. The ASPP will terminate on the earliest of the date on which: the NCIB expires; the maximum number of Shares have been purchased under the NCIB; and the Company terminates the ASPP in accordance with its terms. During the term of the ASPP, the Company will not communicate any material undisclosed or non-public information to the trading staff of the broker; accordingly, the broker may make purchases regardless of whether a trading blackout period is in effect or whether there is material undisclosed or non-public information about the Company at the time that purchases are made under the ASPP. In the event that the ASPP is materially varied, suspended or terminated, the Company will issue a news release advising of such variation, suspension or termination, as applicable. Management of the Company believes that, from time to time, the market price of the Shares may not fully reflect the underlying value of the Shares and that at such times the purchase of Shares would be in the best interests of shareholders. As a result of such purchases, the number of issued Shares will be decreased and, consequently, the proportionate share interest of all remaining shareholders will be increased on a pro rata basis.

08:39 EDT OncoCyte completes validation of TheraSure Transplant Monitoring test - Oncocyte announced that it has completed development of its proprietary TheraSure Transplant Monitoring test for liver transplant patients. This announcement marks the successful completion of technology transfer and Oncocyte's readiness to deploy TheraSure following the Company's acquisition of Chronix Biomedical. "Today's announcement marks the first product to be launched clinically from our Chronix acquisition completed in April 2021. The tech transfer of the proprietary blood based technology used to develop TheraSure was an important undertaking for our R&D team in Germany and our CLIA lab team in Nashville, and I am extremely proud of the herculean effort put forth to meet the aggressive timeline we set last year to put us in a position to launch the liver indication in the first half of 2022," said Ron Andrews, President and CEO of Oncocyte. "Management believes that the streamlined workflow developed by our two expert PCR development teams paves the way for expedited validation of TheraSure for kidney and heart transplants and prepares the Company for the important work ahead to convert the lab workflow into a kit."

08:38 EDT Stryker announces board changes following annual meeting of shareholders - Stryker announced that on May 4, 2022, the company's board of directors approved board leadership and committee assignment changes, naming Sherilyn McCoy to replace Allan Golston as Lead Independent Director, and Mary Brainerd to replace McCoy as Chair of the Governance and Nominating Committee.

08:37 EDT Amdocs launches Americas 5G Experience Lab - Amdocs announced the opening of its Americas 5G Experience Lab in Dallas, Texas. This lab will enable creative organizations serving our connected society to come together and create innovative services leveraging the power of 5G networks. The broader monetization potential of 5G lies in the ability to leverage its capabilities in different ways. This includes onboarding partner applications, slicing the network for enterprises and application providers and enabling software developers to reimagine-the "one size fits all" experiences that exist today.

08:36 EDT RYAH Group provides update on management cease trade order - The RYAH Group Inc. Board of Directors wishes to announce that on May 3, 2022, the Ontario Securities Commission has issued a Management Cease-Trade Order in the matter of RYAH Group Inc. and David R. Richards and Francois C. Desrosiers. This order states that the management of RYAH cannot trade in the Company's securities until two days after RYAH has filed with the Commission all the filings that are currently missing and are required to be made under the Ontario Securities law. The missing filings are the yearly financial statements to December 31, 2021; the management discussion & analysis that accompanies audited financial statements; and the CEO and CFO certificates that are filed at the same time. Since filing the request for the MCTO the Company has worked diligently with its auditors in rapidly completing the audit in accordance with the regulations. There have not been any changes in the RYAH Group's activities and affairs that would qualify as material, for investors. The Company expects to satisfy the provisions of the alternative information guidelines. We do not expect any further defaults or resulting MCTOs. RYAH is working to raise additional capital through a private placement of Subordinate Voting Share Units. The results be announced in a timely fashion. The Issuer intends on continuing to satisfy the provisions of the alternative information guidelines described in section 9 and 10 of National Policy 12-203 so long as it remains in default of the specified requirement. RYAH is not subject to any insolvency proceedings and there is no other material information concerning the affairs of the Issuer that have not been disclosed. The Corporation and the auditors expect that the audited financial statements will be filed on SEDAR by the end of May 2022. The Management and the Board of Directors have endeavoured to continue doing everything possible to assist the auditors in their work so the audit can be completed as soon as possible. When the audit is complete, and the documents have been filed on SEDAR, the Company will report that in a news release. A MCTO is usually granted to give a corporation the time to remedy issues related to continuous disclosure issues while maintaining public trading in the Corporation's securities. Under a MCTO the Directors and Officers of a Corporation cannot trade the Corporation's securities for as long as the issue is not remedied. Once the situation corrected, we expect the MCTO to be lifted. While the situation lasts, officers, directors and anyone with special relationships with the Issuer cannot trade securities issued by the Company. They have all been advised of this black-out, and have agreed to abide by it.

08:35 EDT ConnectOne Bancorp announces partnership with Nymbus - ConnectOne Bank, the insured depository subsidiary of ConnectOne Bancorp, announced its partnership with Nymbus, a cloud-native platform and leading provider of banking technology solutions and core services, to offer digital business banking solutions. "Since inception, ConnectOne Bank's mission has been to offer our clients best-in-class banking experiences tailored to their unique needs. As we diversify our client roster, partnering with Nymbus allows us to continue that mission by building a niche-based vertical powered by leading technology," said Frank Sorrentino III, Chairman & CEO of ConnectOne Bank. "We look forward to working with Nymbus to extend our mission into new segments." ConnectOne plans to launch this new vertical by year-end 2022.

08:34 EDT Bigg Digital Assets' Netcoins appoints Fraser Matthews as president - BIGG Digital Assets is pleased to announce the hiring of Mr. Fraser Matthews as President of Netcoins, effective June 7, 2022. Binns, who has been acting as interim CEO of Netcoins will hand full operational responsibility of Netcoins to Mr. Matthews. Matthews has been working exclusively in the Financial Services industry for the last 15 years having held positions in Toronto, New York, London and Duba

08:33 EDT Belite Bio presents interim results of LBS-008 Phase 1b/2 study - Belite Bio presented interim results of a Phase 1b/2 study of LBS-008 in adolescent STGD1 at The Association for Research in Vision and Ophthalmology Annual Meeting 2022. LBS-008 is Belite Bio's lead asset being developed for the treatment of STGD1 and Dry AMD. To view the full abstract click here. John Grigg, the study's principal investigator and Head Specialty of Ophthalmology at the University of Sydney and Consultant Ophthalmologist at the Sydney Children's Hospitals Network Westmead and Sydney Eye Hospital provided a presentation of the study and data. STGD1 is the most common inherited macular dystrophy. To date there are no treatments. This Phase 1b/2 study examined the safety and tolerability of LBS-008, a retinol binding protein 4 antagonist, in adolescent STGD1 subjects. Preclinical studies have shown that RBP4 inhibition slows disease progression and prevents retinal degeneration in a STGD1 animal model. Childhood-onset STGD1 is characterized by accumulation of bisretinoids which cause progressive retinal atrophy leading to rapid visual loss. Because bisretinoid toxins are derived from circulating vitamin A, reduction of retinol delivery to the eye, via antagonism of RPB4, has been explored as a means to slow disease progression in STGD1. LBS-008 is an orally administered, potent and specific non-retinoid antagonist of RPB4 and has been developed in order to determine whether reduction of circulating RPB4-retinol is a safe and effective treatment approach for STGD1 subjects. The Phase 1b/2 study is a multicenter, single arm, open-label study followed by a 2-year extension to evaluate safety, tolerability and efficacy of LBS-008. Thirteen subjects aged 12-18 years will receive oral LBS-008 daily over a 2-year treatment period. One subject is dosing at 2mg a day. Treatment emergent adverse events, PK/PD, and visual function outcomes will be evaluated. Results: All 13 subjects have received at least 7 months of treatment and have completed the scheduled assessments at the first 6-month interval. The preliminary safety results of the Phase 1b/2 study show that the only drug-related adverse events reported were: delayed dark adaptation, reported by 9 of 13 subjects of which, 6 subjects having recovered; xanthopsia/chromatopsia was reported by 9 subjects, with 3 subjects having recovered; and night vision impairment, reported by 1 patient. All AEs were graded as mild. No severe AEs were reported and no AEs required discontinuation of treatment. No clinically significant findings in relation to vital signs, physical exams, cardiac health, or organ functions. The majority of subjects recorded a gain in BCVA in at least one eye indicating stabilization of visual acuity, including 2 subjects with visual improvement in both eyes. Retinal imaging by fundus autofluorescence photography showed a trend for preventing or slowing expansion of autofluorescence. Areas of questionably decreased autofluorescence were either unchanged or reduced in one or both eyes in 8 of 13 subjects. There was no conversion to definitely decreased autofluorescence in 12 of 13 subjects. 6 subjects showed an improvement of the Ellipsoid Zone defect width in at least one eye, including 3 subjects showing improvements in both eyes. Where quantitative autofluorescence was available qAF was correlated with improvements in VA. Conclusions LBS-008 effectively reduces RBP4 levels by 80-90%. Safe and well tolerated at the 7-month time point; A trend for preventing or slowing expansion of autofluorescence; A trend for improvement of the EZ defect width; Visual acuity has stabilized in a majority of subjects. The Company expects the next near-term data readout in its STGD1 Phase 2 trial to occur in the last quarter of 2022 when all subjects have completed 12 months of treatment.

08:32 EDT China Xiangtai Food enters hosting agreement with Horizon Mining - China Xiangtai Food announced that it has entered into a hosting agreement with Horizon Mining on May 1, 2022, to secure its cryptocurrency mining capacity of up to 6.1 megawatt, MW. In addition, the Company also announced that its first batch of 868 miners will be deployed in Georgia, U.S. on May 5, 2022. The site is located in Georgia Center for Innovation & Manufacturing in Macon City, Georgia. The Company expects to have its final inspection and power-up on the site today. The first batch of 868 miners will be deployed simultaneously and expected to operate and mine Bitcoin once finished all required work. The hosting team will prepare for initiating the mining operations by setting up the miners and performing the final testing. In addition, the next batch of 560 miners will be deployed in the second week of May 2022. Running at full capacity, the total of 1,428 miners, representing a hash power of 132PH/s, are expected to mine 0.56 BTC per day or generate daily revenue of approximately $22,000. Lucas Wang, Chairman and Chief Executive Officer of the Company, commented, "We are excited to announce that the operation of cryptocurrency miners marks the new era of the Company and accelerates the Company's expansion strategy in North America. We expect to deepen the collaboration with Horizon to expand further as we deploy more miners in the near future. We are confident that we will be able to grow significantly and deliver greater value to shareholders."

08:29 EDT Newell Brands names Chris Peterson President & CFO - Newell Brands announced that Chris Peterson, Chief Financial Officer & President, Business Operations, has been named President & Chief Financial Officer, effective immediately. He will continue to lead all aspects of the company's financial operations and maintain oversight of Supply Chain, Procurement, IT, Real Estate and Global Business Services. Chris will continue to report to the company's Chief Executive Officer, Ravi Saligram. "I am very pleased to announce that Chris Peterson has been appointed President & Chief Financial Officer of Newell Brands and congratulate him on this well-deserved recognition. Chris has been an excellent partner to the Business Unit CEOs and me in the turnaround journey as we create a new Newell that drives sustainable, profitable growth," Newell Brands' CEO Ravi Saligram stated. Since joining Newell in 2018, Peterson has led the company's complexity reduction efforts including SKU rationalization, consolidating multiple ERP systems, eliminating unnecessary applications and reducing legal entities. "Chris is driving operational excellence through a clear focus on automation, productivity improvements and leading Project Ovid, Newell's supply chain transformation. He has been a driving force behind strengthening Newell's balance sheet and meaningfully improving cash flow, reducing the cash conversion cycle from 115 days to 68 in the last three years. Under his leadership, our leverage ratio has steadily come down and S&P recently upgraded us to investment grade," Saligram continued. "I also personally appreciate Chris's steady hand and proactive execution in steering the organization through a difficult period of supply constraints and high inflation. I look forward to continuing to work closely with him on strategic and enterprise-wide initiatives to drive shareholder value."

08:28 EDT In8bio unveils iPSC Platform at ASGCT meeting - IN8bio announced the Company's new induced pluripotent stem cell based gamma-delta T cell platform. We have demonstrated that we are one of the few companies than can differentiate iPSC-derived immune cells and the first to produce both iPSC-derived Vdelta1 and Vdelta2 gamma-delta T cell subtypes. This platform represents a new phase in IN8bio's growth as it advances technology that is designed to enable scaled manufacturing of 'off-the-shelf' cellular therapies. The Company will present the data at the American Society for Gene & Cell Therapy 25th Annual Meeting in Washington, DC, May 16 to 19, 2022. In addition, Lawrence Lamb, Ph.D., CSO of IN8bio, will present a podium discussion in Ballroom B on "The Next Generation of gamma-delta T Cell-based Therapies" on May 16, 2022.

08:26 EDT Biogen, MedRhythms enter license agreement to develop MR-004 - Biogen and MedRhythms have entered into a license agreement to develop and commercialize MR-004, an investigational prescription digital therapeutic for the potential treatment of gait deficits in multiple sclerosis, or MS. The collaboration combines MedRhythms' digital expertise with Biogen's global footprint in MS in order to address significant unmet patient needs.

08:25 EDT Enphase Energy expands battery storage in Georgia - Enphase Energy announced that installers of Enphase products in Georgia have seen growing deployments of Enphase Energy Systems powered by IQ Microinverters and IQ Batteries, as homeowners in the coastal state prepare for another hurricane season of increased storm activity. "As outages and energy security become an increasing concern, we're witnessing a growing customer demand for reliable and durable battery backup systems," said Russ Seifert, chief executive officer at Creative Solar USA, an Enphase Gold level installer. "We're proud to offer Enphase IQ Batteries to our customers so that they are prepared to power their essentials and have peace of mind during power outages."

08:24 EDT Entera Bio files multiple US patent applications for its platform technology - Entera Bio announced that it recently filed multiple U.S. patent applications to "further strengthen the Company's patent protection and support future developments," the company said. These patent applications address an optimized platform technology intended to be utilized for future therapeutic applications. In parallel with the platform technology patent, the Company filed several patent applications related to the oral delivery of specific molecules or families of molecules, including parathyroid hormone, glucagon-like peptide-1, GLP-2, human growth hormone, and others, utilizing the newly optimized oral delivery platform for indications including osteoporosis, hypoparathyroidism, non-union bone fractures, short bowel syndrome, and GH deficiency, and others. "We believe Entera is at the forefront of innovating and improving the oral delivery of large molecule proteins. We've filed a substantial number of new patent applications intended to fortify our robust intellectual property position as we evaluate engaging in additional strategic partnerships," stated Entera Chief Executive Officer, Spiros Jamas. "We see opportunities with GLP's, orphan indications, and the extension of major categories of biologic drugs, which have the potential for oral delivery through Entera's platform. Concurrently, we are working on global partnering of our lead asset, EB613, as it moves toward a pivotal Phase 3 for the treatment of osteoporosis."

08:23 EDT Insight Enterprises sees FY22 low double digit net sales growth

08:22 EDT FuelCell extends term of agreement with ExxonMobil - FuelCell Energy announced that it has extended the term of its joint development agreement with ExxonMobil Technology and Engineering Company through December 31, 2022. The agreement will enable the companies to continue working to advance fuel cell carbon capture and storage technology closer to commercialization and to explore market applications with a focus on three areas: 1) Continue technology development to enhance understanding of fuel cell operating envelope for various carbon capture applications. 2) Complete technology readiness in support of a potential deployment of the technology in a fuel cell module demonstration for capturing carbon at an ExxonMobil facility. 3) Conduct a joint market study to define application opportunities, commercialization strategies, and identify partners for potential demonstration for industrial carbon capture applications. "Extending the scope of our long-standing agreement is evidence of ExxonMobil and FuelCell Energy's joint desire to accelerate commercial deployment of differentiated fuel cell carbon capture technology," said Jason Few, CEO of FuelCell Energy. "We are excited to build on the recent achievement of a key technical milestone as we advance toward the goals of a carbon capture demonstration and, ultimately, full scale deployment. We believe carbon capture is an essential requirement toward achieving global climate objectives."

08:20 EDT Orezone announces drill results from Bombore Gold project - Orezone Gold is pleased to provide ongoing drill results from the Phase III program along the P17 mineralized trend at the Bombore Gold Project, located in Burkina Faso. The focus of the Phase III drilling at the P17 Trend is as follows: To better define the continuity of the repeat, folded high-grade granodiorite mineralized zones at P17S; To test the continuity and expansion potential of P17 located 1 km to the north of P17S and which was last drilled in 2013. The drill results continue to be very positive confirming the following: Down-plunge continuity of the mineralized zones at P17S; Mineralized system at P17S remains open above and below the drilled portion of the granodiorite on most sections, which will warrant follow-up definition drilling; Significant new intercept on the deeper extension of the main zone beneath the P17S-NE deposit and outside of the current mineral resource envelopes indicating good potential to further expand the main P17S deposit; Results from P17 have confirmed continuity of existing shallowly north-plunging mineralized zones and have further extended the P17 Trend, with a new high-grade shallow intercept to the north. P17 now remains totally open at depth and to the north. P17S Drilling Highlights: 16.00 m of 1.66 g/t Au from 48 m in hole BBD1100; 14.70 m of 2.13 g/t Au from 190 m in hole BBD1102; 25.00 m of 1.63 g/t Au from 83 m in hole BBD1103; 9.25 m of 3.18 g/t Au from 294.30 m in hole BBD1113; 30.00 m of 2.12 g/t Au from 99 m including 2.00 m of 8.80 g/t Au in hole BBD1114; 30.00 m of 1.63 g/t Au from 124 m including 10.00 m of 2.98 g/t Au from 124 m and 5.00 m of 2.26 g/t Au from 166 m in hole BBD1115. P17 Drilling Highlights: 8.80 m of 4.34 g/t Au from 80.20 m in hole BBD1086;8.00 m of 2.36 g/t Au from 59 m in hole BBD1088; 22.00 m of 1.11 g/t Au from 124 m including 5.00 m of 2.29 g/t Au from 124 m in hole BBD1094; 57.00 m of 1.01 g/t Au from 34 m including 14.00 m of 1.57 g/t Au from 54 m and 5.00 m of 2.50 g/t Au from 86 m in hole BBD1096. Dr. Pascal Marquis, SVP of Exploration stated, "Drilling to date at P17S continues to be very successful as demonstrated by excellent continuity of the gold mineralization, which remains open along trend and at depth, including extensions outside of the current resource model. I am also very encouraged by the drilling results at the P17 zone, which had not been drilled since 2013. Current results have confirmed that P17 is now open to the north and at depth and will warrant further drilling. A third drill rig has now been mobilized to accelerate the ongoing drill program."

08:18 EDT Moleculin Biotech's Phase 1/2 Annamycin study in AML allowed to proceed - Moleculin Biotech has received allowance from the Polish Department of Registration of Medicinal Products - URPL -, as well as the requisite Ethics Committee approval, to proceed with its Phase 1/2 clinical trial in Poland of Annamycin in combination with Cytarabine ) in the treatment of subjects with acute myeloid leukemia - AML - who are refractory to or relapsed after induction therapy. The Phase 1/2 L-ANN /ARA-C combination trial, an open label trial, builds on the safety and dosage data from the two successfully concluded single agent Annamycin AML Phase 1 trials in the U.S. and Europe and the preclinical data discussed below. The study is expected to commence patient enrollment in the first half of 2022. Annamycin is the company's next-generation anthracycline that has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin, as well as demonstrating the ability to avoid the multidrug resistance mechanisms that typically limit the efficacy of doxorubicin and other currently prescribed anthracyclines.

08:13 EDT Royal Caribbean says operating cash flow 'turning positive in April' - The Group's fleet size expanded to 63 with the delivery of Wonder of the Seas and Celebrity Beyond in the first quarter and early second quarter, respectively. These ships, along with six other new ships which have joined the fleet over the last 20 months and represent over 10% of total capacity, are significantly contributing to yield growth and profitability. The Group expects its entire fleet of 63 ships will be operational by the beginning of the 2022 summer season. The Group is now offering cruises in almost all of its destinations. Australia, one of the last remaining countries to re-open, announced the resumption of cruising effective April 2022. The Group expects to return to Australia for the local summer season in the fourth quarter of 2022. China remains closed to cruising due to the ongoing lockdowns. While the Group remains optimistic to capture long-term growth opportunities in that market, ships planned for China have been temporarily redeployed to other markets. The Group expects to operate approximately 10.3 million Available Passenger Cruise Days for the second quarter with load factors of 75% to 80%. The Group also expects cash flow from ships in operation to be positive in the second quarter. Operating cash flow significantly improved throughout the first quarter and is turning positive in April.

08:12 EDT Qiagen receives CE-IVD certification for NeuMoDx HSV 1/2 Quant Assay - Qiagen announced that its NeuMoDx HSV 1/2 Quant Assay for the quantification and differentiation of herpes simplex virus type 1, or HSV-1, DNA and/or herpes simplex virus type 2, or HSV-2, has received CE-IVD certification for the European Union and other countries that accept this marking. This approval supports Qiagen's strategy to expand the menu of tests available for use on the NeuMoDx 96 and 288 Molecular Systems, which offer one of the broadest menus on the market now with 15 CE-IVD tests available.

08:11 EDT Royal Caribbean provides update on bookings - Booking volumes in the first quarter improved consistently week-over-week and reached typical Wave levels at the end of the quarter. Bookings have now been surpassing comparable 2019 levels for the last two months with particularly strong trends for North America based itineraries. In addition, the elevated cancellations experienced earlier in the year returned to pre-Omicron levels as cases subsided in February. While load factors for sailings in the second half of 2022 are currently slightly below historical levels, consumers are booking their cruises closer to sailing and the Group is capitalizing on that healthy close-in demand to improve load factors. For the full year and the second half of 2022, pricing remains higher than in 2019 both including and excluding FCCs. Bookings for Europe sailings improved throughout the first quarter but softened due to the war in Ukraine with a bigger impact on Baltic itineraries. While bookings for Europe are now exceeding 2019 levels for the same period, the situation in Ukraine is expected to weigh on load factors in Europe this summer. "The performance of our core business continues to strengthen, fueled by strong demand and excellent operational execution," said Naftali Holtz, CFO at Royal Caribbean Group. "Our near-term focus is to return to full operations and profitability as we execute on our recovery and build for long term success."

08:09 EDT Incyte receives EC approval for Jakavi - Incyte announced the European Commission, or EC, has approved Jakavi for the treatment of patients aged 12 years and older with acute or chronic GVHD who have inadequate response to corticosteroids or other systemic therapies. Ruxolitinib is marketed as Jakavi by Novartis in Europe and as Jakafi by Incyte in the United States.

08:07 EDT Flagstar Bancorp appoints Mark Herron as Chief Brand Officer - Flagstar Bank has hired Mark Herron as Chief Brand Officer for the company. Herron most recently served as executive vice president and chief marketing officer for People's United Bank in Bridgeport, Conn. Previously, he held various senior positions in marketing and sales for BB&T in Winston-Salem, N.C.

08:07 EDT MaxLinear to acquire Silicon Motion for $114.34 per share consideration - MaxLinear (MXL) and Silicon Motion (SIMO) announced that they have entered into a definitive agreement under which MaxLinear will acquire Silicon Motion in a cash and stock transaction that values the combined company at $8B in enterprise value. In the merger, each American Depositary Share, or ADS, of Silicon Motion, which represents four ordinary shares of Silicon Motion, will receive $93.54 in cash and 0.388 shares of MaxLinear common stock, for total per ADS consideration of $114.34. Combined revenues are expected to be more than $2B annually and are supported by the technology breadth to address a total market opportunity of roughly $15B. The transaction is expected to generate annual run-rate synergies of at least $100M to be realized within 18 months after the transaction closes and is expected to be immediately and materially accretive to MaxLinear's non-GAAP earnings per share and cash flow. Under the terms of the definitive agreement, the transaction consideration will consist of $93.54 in cash and 0.388 shares of MaxLinear stock for each Silicon Motion ADS and $23.385 in cash and 0.097 shares of MaxLinear common stock for each Silicon Motion ordinary share not represented by an ADS. Upon closing of the transaction, MaxLinear shareholders will own approximately 86% of the combined company and Silicon Motion stockholders will own approximately 14% of the combined company. Based on the closing price of MaxLinear shares on May 4, the implied value of the total transaction consideration for Silicon Motion is $3.8B. MaxLinear intends to fund the $3.1B of cash consideration with cash on hand from the combined companies and fully committed debt financing from Wells Fargo Bank, N.A. The transaction is not subject to any financing conditions and is expected to close by the first half of calendar 2023, pending satisfaction of customary closing conditions, including Silicon Motion shareholders' approval and regulatory approvals in various jurisdictions.

08:06 EDT Sonim receives $9.5M rugged phone purchase order from U.S. carrier - Sonim announced purchase orders totalling $9.5M from a top U.S. carrier customer. The purchase orders cover initial stocking inventory for two of the company's next-generation ultra-rugged phones to be introduced in 2022 - the XP5 Plus feature phone and Sonim's XP10 5G rugged smartphone. The XP5 Plus is expected to be available this summer, and Sonim's new XP10 rugged 5G smartphone device are expected to begin shipments in the fall.

08:05 EDT Kellogg affirms FY financial guidance

08:03 EDT Keros Therapeutics expects cash to fund operations into Q1 of 2024 - Keros' cash and cash equivalents as of March 31, 2022 was $228.6 million compared to $230.0 million as of December 31, 2021. Keros expects that the cash and cash equivalents it had on hand at March 31, 2022 will fund its operating expenses and capital expenditure requirements into the first quarter of 2024.

08:00 EDT Maxlinear trading resumes

07:59 EDT Draganfly to deploy another 5 medical response drone systems into Ukraine - Draganfly announces that the Company will provide Revived Soldiers Ukraine, RSU, with five highly specialized Medical Response Drones using funds provided by DroneAid: Ukraine. DroneAid: Ukraine is a non-profit North American campaign supporting RSU in its humanitarian aid operations by ensuring it has access to advanced unmanned aerial vehicles and crucial medical supplies and equipment. "It is an honor to supply RSU with five specialized Medical Response Drones using funds raised through DroneAid: Ukraine," Cameron Chell, CEO of Draganfly. "Across Ukraine, there is an urgent need for temperature-sensitive medical supplies and life-saving equipment. Our Medical Response Drones will help RSU safely provide aid to affected Ukrainians in dangerous and hard-to-reach areas."

07:57 EDT Biogen, MedRhythms to develop, commercialize MR-004 - Biogen and MedRhythms have entered into a license agreement to develop and commercialize MR-004, an investigational prescription digital therapeutic for the potential treatment of gait deficits in multiple sclerosis. The collaboration combines MedRhythms' digital expertise with Biogen's leadership and global footprint in MS in order to address significant unmet patient needs. MedRhythms is developing next-generation prescription digital therapeutics across a broad range of indications in neurology via a technology platform that leverages advancements in neuroscience and music to target improved walking and mobility. MR-004 is MedRhythms' pipeline candidate in MS, which aims to improve gait and gait-related aspects of movement, potentially providing MS patients with improved independence related to mobility. If approved, MR-004 has the potential to become the first prescription digital therapeutic for gait deficit in MS. MedRhythms is currently conducting two ongoing feasibility studies for MR-004, and, based on the readout of the first study, plans to initiate a registrational trial in the near future. Under the terms of the agreement, Biogen will make an upfront payment of $3 million to MedRhythms. Should certain development and commercial milestones be achieved, MedRhythms will be eligible to receive up to $117.5 million in potential milestone payments. MedRhythms is also eligible to receive tiered royalties in the high-single digits to low-teens on potential global sales.

07:56 EDT HCW Biologics to present two groups of novel immunotherapeutics - HCW Biologics is presenting two groups of novel immunotherapeutics created with its proprietary and powerful Tissue factOr-Based fusIon discovery platform at the 105th Annual Meeting of the American Association of Immunologists, AAI, or Immunology 2022. "HCW Biologics has invented a unique solution for providing clinical-grade fusion proteins for therapeutic use," stated Dr. Hing Wong, Founder and CEO of HCW Biologics. "Immunology 2022 is our opportunity to showcase the power and versatility of our TOBI discovery platform. The first program will feature the benefits of the use of our fusion proteins without the need of feeder cells to address the challenges for supporting a multiple-dose infusion of memory-like NK cells in the clinic for cancer." Dr. Wong continued, "Immunology 2022 also provides us with an ideal audience for the introduction to our program for the expansion of regulatory T cells for the treatment of autoimmune and inflammatory diseases. The benefits of Treg cells in the treatment of inflammatory diseases are well-known, but manufacturing these therapies are labor intensive, lack consistency, and are difficult to scale. HCW Biologics has developed an approach that does not rely on magnetic beads. We also showcase our proprietary human monoclonal antibodies for generating target-specific Treg cells. We believe our unique approach could potentially open up Treg therapy as an adoptive cell therapy that could address a broad range of inflammatory pathologies." Oral and Poster Presentation for Expansion of Memory-Like NK Cells: Title: "A feeder cell-free activation and expansion strategy to generate memory-like NK cells sufficient for off-the-shelf multi-dose adoptive cell therapy." Title: "Robust human regulatory T cell expansion with fusion proteins HCW9302 and HCW9213 circumvents need for magnetic-bead or feeder cell approaches for adoptive cell therapy."

07:54 EDT Clearside Biomedical announces poster presentations at ARVO 2022 - Clearside Biomedical announced that several poster presentations were delivered on Clearside's proprietary suprachoroidal delivery platform, XIPERE, and gene therapy delivery utilizing Clearside's SCS Microinjector at the Association for Research in Vision and Ophthalmology, ARVO, 2022 Annual Meeting. At ARVO, Viral Kansara, PhD, Vice President, Preclinical Development at Clearside Biomedical, presented a poster entitled, "Targeting, Compartmentalization and Durability of Suprachoroidally Injected Small Molecule Suspensions" that summarized the preclinical and clinical evaluation of SCS Microinjector-based suprachoroidal delivery, and its synergy with small molecule suspensions for a potentially safe, efficacious and durable ocular delivery platform. The studies showed several key findings: SC injected small molecule suspensions, at studied dose levels and duration, were well-tolerated in rabbits. Ex-vivo and in-vivo imaging confirmed posterior spread and opening of the SCS immediately after the SC injection. SC injected small molecule suspensions achieved high and durable drug levels in the retina and retina-choroid-sclera. SC injected small molecule suspensions demonstrated targeted and compartmentalized drug levels to the chorioretina, and low to minimal drug exposure in the lens, vitreous humor, and aqueous humor. SC injected axitinib and triamcinolone acetonide suspensions demonstrated signs of biological activities in preclinical animal models and in the clinic. Partner Presentations: Several posters were presented at ARVO related to XIPERE for suprachoroidal use: "National Physician Survey on Clinical Practice Patterns for the Treatment of Noninfectious Uveitis." "Suprachoroidal Triamcinolone Acetonide Injectable Suspension for Macular Edema Associated with Uveitis: Effect of Disease Characteristics on Clinical Outcomes." "Suprachoroidal Triamcinolone Acetonide Injectable Suspension for Macular Edema Associated with Uveitis: Integrated Analysis of Two Clinical Trials." "Suprachoroidal Triamcinolone Acetonide Injectable Suspension for Macular Edema Associated with Uveitis: Outcomes by Anatomic Subtypes in PEACHTREE." "Suprachoroidal Triamcinolone Acetonide Injectable Suspension for Macular Edema Associated with Uveitis: Visual and Anatomic Outcomes by Age." Two presentations were delivered on REGENXBIO asset RGX-314 administered via Clearside's SCS Microinjector: "Suprachoroidal Delivery of RGX-314 Gene Therapy for Neovascular AMD: The Phase II AAVIAT Study" and "Suprachoroidal Delivery of RGX-314 for Diabetic Retinopathy: The Phase II ALTITUDE Study." Retina World Congress 2022: Panelist - "New Pathways in Retinal Diseases." Presentation, "Longer-term Visual Acuity Outcomes and Anti-VEGF Therapy Intensity in Neovascular AMD, DME, and RVO-Related Macular Edema: A Real-World Analysis of 130,247 Patient Eyes"

07:53 EDT DT Midstream reaffirms 2022 adjusted EBITDA view $770M-$810M - "Our first quarter financial results give us high confidence in meeting our financial goals," said Jeff Jewell, Executive Vice President and CFO. "Major investments for 2022 remain well on track and will provide strong growth this year. Additionally, our commercial progress has us in a great position to achieve our goals in 2023 and beyond."

07:51 EDT KemPharm announces submission of IND application for Phase 2 trial of KP1077 - KemPharm announced the submission of an Investigational New Drug, IND, application seeking authorization from the U.S. Food and Drug Administration, FDA, to initiate a Phase 2 clinical trial evaluating KP1077 as a treatment for idiopathic hypersomnia, IH, a rare neurological sleep disorder. KemPharm successfully completed the pre-IND meeting process with the FDA in February 2022. During these interactions, KemPharm received confirmation that additional non-clinical studies were not needed to advance KP1077 into clinical development due to the abundance of data already available on serdexmethylphenidate . "We are excited to begin the clinical development process for KP1077 as a potential treatment for IH, a rare sleep disorder characterized by multiple, debilitating symptoms for which few treatment options exist," stated Travis Mickle, Ph.D., President and Chief Executive Officer of KemPharm. "Our optimism surrounding KP1077 is based on the preclinical and clinical data regarding SDX, which includes the recent results from a Phase 1 clinical trial exploring the safety and pharmacokinetics of SDX administered in doses higher than currently approved. The data suggest that SDX produces a smoother, more gradual release of d-MPH that may avoid the adverse events associated with large and rapid exposure fluctuations that may be experienced with other stimulant-based therapies. We believe KP1077 could provide an improved treatment option for patients with IH and other sleep disorders by addressing the most debilitating symptoms of IH, including excessive daytime sleepiness (EDS), extreme difficulty waking up, severe "brain fog", and falling asleep unintentionally and/or at inappropriate times, even after adequate or prolonged nighttime sleep." Once the clinical investigation proposed in the IND has been cleared to proceed by the FDA, KemPharm plans to initiate its Phase 2 clinical trial of KP1077 in IH as early as the second half of 2022.

07:50 EDT Skye Bioscience reports publication of preclinical data on SBI-100 - Skye Bioscience announced that the peer-reviewed journal International Journal of Pharmaceutics published preclinical data demonstrating stronger and longer-lasting reduction of intraocular pressure when Skye's proprietary molecule, SBI-100, is formulated as a nanoemulsion containing the mucoadhesive agent Carbopo 940. The results of the research were published March 2022 in a paper, "Impact of mucoadhesive agent inclusion on the intraocular pressure lowering profile of undefined9-tetrahydrocannabinol-valine-hemisuccinate loaded nanoemulsions in New Zealand white rabbits," authored by C. Sweeney et al. from the University of Mississippi. Skye, in collaboration with UM, previously published preclinical data demonstrating SBI-100 formulated as a nanoemulsion achieved greater reduction of intraocular pressure in non-pigmented rabbits than both latanoprost and timilol1, the current first and second line treatments for glaucoma, respectively. The current study was undertaken to determine if the inclusion of a mucoadhesive agent could prolong the intensity and duration of action of the THC-VHS-NE formulation through increased residence time or penetration, or both, to potentially achieve once- or twice- a day dosing. In this study sponsored by Skye, researchers at the University of Mississippi compared the reduction of IOP in normotensive rabbits with a single treatment of THC-VHS-NEC compared to latanoprost, the commercial standard of care; THC-NEC; and THC-VHS-NE. When comparing each treatment group, THC-VHS-NEC, Skye's SBI-100 Opthalmic Emulsion, demonstrated the greatest intensity and duration of IOP-lowering. In comparison to THC-VHS-NE, THC-NEC and commercial latanoprost, THC-VHS-NEC exhibited a prolonged duration of action. THC-NEC and THC-VHS-NE formulations respectively produced an average maximum drop in IOP of 3.7 mmHg at 60 minutes and 4.8 mmHg at 150 min, while the IOP-lowering effect lasted for 240 and 360 min, respectively, in the treated eye. In contrast, SBI-100 Ophthalmic Emulsion lowered IOP by 4.5 mmHg at 60 min and maintained this drop for at least 480 min in the treated eye. A significant difference in IOP-lowering was also observed between SBI-100 Ophthalmic Emulsion and commercial latanoprost ophthalmic solution. The average maximum drop in IOP with SBI-100 Ophthalmic Emulsion of 4.5 mmHg at 60 min was almost twice that obtained with commercial latanoprost ophthalmic solution at 60 min. Moreover, latanoprost maintained IOP 10% below baseline for only 360 min, whereas SBI-100 Ophthalmic Emulsion maintained the IOP- lowering effect for at least 480 min.

07:48 EDT DraftKings completes acquisition of Golden Nugget Online Gaming - DraftKings (DKNG) announced the completion of its acquisition of Golden Nugget Online Gaming (GNOG). The GNOG Acquisition will, among other things, allow DraftKings to "leverage Golden Nugget's established brand to broaden its reach into new customer segments and enhance the combined company's iGaming product offerings through DraftKings' vertically-integrated tech stack and Golden Nugget Online Gaming's unique capabilities - including Live Dealer," the company said. "Acquiring Golden Nugget Online Gaming gives us synergies across our business," said Jason Robins, Chairman and CEO of DraftKings. "We anticipate that this acquisition will provide meaningful revenue uplift by utilizing our data-driven marketing capabilities and a dual brand iGaming strategy, gross margin improvement opportunities, and cost savings across external marketing and SG&A. I am proud to welcome the Golden Nugget Online Gaming team to the DraftKings family."

07:46 EDT Alpha Metallurgical raises guidance for cost of coal sales - Alpha is increasing its cost of coal sales guidance due to the elevated pricing environment in global coal markets. Higher sales prices result in higher royalties and severance taxes, which are part of our costs of coal sales. These circumstances, alongside increased labor costs and persistent inflationary pressure on certain materials, have contributed to the guidance change announced today. Met segment cost of coal sales are now expected to be between $101.00 per ton and $107.00 per ton for the full year, up from the prior guidance range of $88.00 per ton to $92.00 per ton. Cost of coal sales for the All Other category are expected to remain unchanged in the range of $58.00 per ton to $62.00 per ton.

07:45 EDT Xos announces partnership with Thermo King - Xos announced a partnership with Thermo King to jointly develop a refrigerated commercial vehicle prototype that is 100% battery-electric. The battery-electric refrigerated prototype vehicle will support fresh and frozen applications and will be used in field trials by Xos and Thermo King customers. "We're proud to partner with a leader in transport refrigeration like Thermo King to continue delivering the best possible electric solutions for our end-customers," said Jose Castaneda, Vice President of Business Development at Xos. The partnership also includes a non-exclusive agreement for Xos to use Thermo King's refrigeration units on the Xos Hub mobile charging station and a non-exclusive agreement for Thermo King to use Xos' Lyra Series battery systems on its all-electric trailer refrigeration unit trucks and trailers.

07:45 EDT Verizon announces international stadium and venue strategy - Verizon (VZ) announced a dedicated strategy, specifically designed for stadium and venue customers located in Europe and the Asia-Pacific region. This new strategy leverages Verizon's innovative private 5G technology, its extensive industry expertise as well as key new technology partnerships. Extreme Networks (EXTR) is named as a technology partner within Verizon's international stadium partner ecosystem. Extreme and Verizon will deliver High-Density Wi-Fi to future event venues. Extreme announced that it has selected Verizon Business as its technology deployment partner for the planned roll out of Wi-Fi solutions at Manchester United Football Club's Old Trafford stadium. The two companies will provide HD-Wi-Fi connectivity to enhance the Club's digital services such as mobile ticketing and touchless transactions.

07:42 EDT Sunrun raises FY22 Solar Energy Capacity Installed growth view to 25% or greater - Last night, Sunrun management said they now expect Solar Energy Capacity Installed growth to be 25% or greater for the full-year 2022, an increase from the prior guidance of 20% or greater. Total Value Generated is expected to grow meaningfully faster than Solar Energy Capacity Installed for the full-year 2022, with Net Subscriber Values of above $10,000 in Q3, the company noted. For the second quarter, management expects Solar Energy Capacity Installed to be in a range between 235 and 245 megawatts.

07:42 EDT Cellebrite announces upcoming release of Cellebrite Premium - Cellebrite announced the upcoming release of the SaaS-based version of Cellebrite Premium. Cellebrite Premium is an advanced access solution, providing unlock and extract capabilities for most iOS as well as the leading Android devices. The new offering, which is part of Cellebrite's industry-leading DI suite of Solutions, will be previewed at the upcoming Techno Security & Digital Forensics Conference in Myrtle Beach, South Carolina, from May 9th to May 12th, 2022. The solution aims to allow law enforcement agencies to benefit from flexible licensing options and reduce ongoing hardware and maintenance costs. In addition, the SaaS-based version of Premium aims to provide agencies immediate access to the most up-to-date capabilities, allowing more law enforcement organizations to decentralize device access and data collection efforts as they work to expedite digital investigations and reduce case backlogs.

07:39 EDT Chindata provides update on status under HFCAA - Chindata Group Holdings announced that the Company is aware of the fact that it was provisionally named by the United States Securities and Exchange Commission as a Commission-Identified Issuer under the Holding Foreign Companies Accountable Act of the United States on May 4th, 2022, following the Company's filing of the annual report on Form 20-F for the fiscal year ended December 31, 2021 with the SEC on April 29, 2022. The Company understands that the SEC made such identification pursuant to the HFCAA and its implementation rules issued thereunder. This indicates that the SEC has determined the Company used a registered public accounting firm, whose working paper cannot be inspected or investigated completely by the Public Company Accounting Oversight Board of the United States to issue the audit opinion for the Company's financial statements for the fiscal year ended December 31, 2021. In accordance with the HFCAA, the SEC shall prohibit a company's shares or American depositary shares from being traded on a national stock exchange or in the over-the-counter trading market in the United States if the company has been identified by the SEC for three consecutive years due to PCAOB's inability to inspect the auditor's working paper. The Company will continue to monitor market developments and actively explore all strategic options to protect the interests of its stakeholders.

07:35 EDT Arbutus Biopharma announces upcoming milestones - Anticipated Milestones in 2022: Dose first patient in the AB-729-202 Phase 2a clinical trial evaluating AB-729, in combination with VTP-300, Vaccitech plc's therapeutic vaccine and nucleos(t)ide analogue therapy in cHBV patients in the first half of 2022. Present new on-treatment data as well as long-term off-treatment data for cHBV patients in the AB-729-001 clinical trial at a medical conference later this year. Report initial data from the AB-729-201 Phase 2a clinical trial evaluating AB-729 in combination with ongoing NA therapy and short courses of PEG-IFNalpha-2a in cHBV patients in the second half of 2022. Report initial data from the Phase 2a clinical trial evaluating AB-729 in combination with vebicorvir, Assembly Biosciences lead HBV core inhibitor, and an NA in cHBV patients in the second half of 2022. Report data set from the AB-836-001 clinical trial evaluating multiple doses of AB-836 in cHBV patients in the first half of 2022. Complete IND-enabling studies for two oral compounds to treat HBV in the second half of 2022. Advance an oral compound that inhibits the SARS-CoV-2 nsp5 main protease into IND enabling studies in the second half of 2022. Continue to explore a potential oncology indication with our oral PD-L1 program.

07:33 EDT Silicon Motion trading halted, news pending

07:33 EDT Maxlinear trading halted, news pending

07:31 EDT CareDx announces new data on AlloMap Kidney - CareDx announced the publication of new data demonstrating that AlloMap Kidney gene-expression profiling predicts the probability of allograft rejection for both antibody-mediated rejection and T cell-mediated rejection. The new data, published in Biomarkers in Medicine, combining multiple data sets, including the multi-center, prospective OKRA study, shows that AlloMap Kidney can reliably discriminate rejection from quiescence in kidney transplant patients with a negative predictive value of 95%. The results are consistent with previously published clinical validation study results. "This multi-center study delivers further evidence that AlloMap Kidney comprehensively assesses immunological risk of rejection," said Reg Seeto, CEO and President of CareDx. "This moves us one step closer to being able to offer our multimodality KidneyCare solution to clinicians, an innovative new advancement for kidney transplant patients."

07:29 EDT Intercept announces Advanz Pharma to acquire Ocaliva for up to $450M - Intercept Pharmaceuticals announced it has entered into an agreement to sell to Advanz Pharma, a pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe, certain foreign subsidiaries and rights regarding Intercept's international operations, including a license to commercialize Ocaliva outside of the U.S. "This agreement marks an important step forward for Intercept as the value it brings to our company allows us to significantly strengthen our balance sheet while providing us with greater strategic optionality during this transformational year and beyond," said Jerry Durso, President and Chief Executive Officer of Intercept. "We are committed to investing in our core focus areas in the U.S., including our PBC business, potential future activities in NASH, and our advancing and expanding pipeline. At the same time, we are confident that the strong international team will continue to build on our successful PBC business as they transition to Advanz Pharma." Upon closing of the transaction: Intercept will receive consideration in the amount of $405M upfront, subject to customary working capital and other adjustments. The company will receive an additional $45M from Advanz Pharma contingent upon receipt of an extension of pediatric orphan exclusivity in Europe. Intercept will receive royalties on any future net sales of obeticholic acid in NASH outside of the U.S., should Advanz Pharma pursue marketing authorization for this indication in ex-U.S. regions. Intercept will continue to be responsible for the manufacturing and supply of obeticholic acid globally and Advanz Pharma will be responsible for packaging, distribution and commercialization of the therapy in all markets outside of the U.S. The majority of Intercept employees outside of the U.S. will transfer to Advanz Pharma. The remaining international employees will continue to work for Intercept. Intercept will maintain an office in the UK to manage its global supply chain, support its quality organization, and support its global clinical trials.

07:28 EDT LexinFintech updates status under HFCAA - LexinFintech Holdings updates its status under the Holding Foreign Companies Accountable Act. The Company was provisionally named by the United States Securities and Exchange Commission as a Commission-Identified Issuer on May 4, 2022, following the Company's filing of the annual report on Form 20-F for the fiscal year ended December 31, 2021 with the SEC on April 29, 2022. The Company understands that this identification under the HFCAA and its implementation rules issued thereunder indicates that the SEC determines that the Company used a registered public accounting firm whose working paper cannot be inspected or investigated completely by the Public Company Accounting Oversight Board of the United States to issue the audit opinion for its financial statements for the fiscal year ended December 31, 2021. In accordance with the HFCAA, the SEC shall prohibit a company's shares or American depositary shares from being traded on a national stock exchange or in the over-the-counter trading market in the United States if the company has been identified by the SEC for three consecutive years due to PCAOB's inability to inspect the auditor's working paper. The Company has been actively exploring possible solutions to protect the interest of its stakeholders. The Company will continue to comply with applicable laws and regulations in both China and the United States and strive to maintain its listing status on the Nasdaq Stock Market.

07:20 EDT Jounce Therapeutics sees cash, cash equivalents funding operations into Q3 2023 - Based on its current operating and development plans, Jounce reiterates its financial guidance for 2022. Gross cash burn on operating expenses and capital expenditures for the full year 2022 is expected to be approximately $115.0 million to $130.0 million. Given the strength of its balance sheet, Jounce expects its existing cash, cash equivalents and investments to be sufficient to enable the funding of its operating expenses and capital expenditure requirements through the third quarter of 2023.

07:18 EDT Arvinas announces anticipated milestones and expectations - ARV-471: Present data from the VERITAC Phase 2 expansion trial - 2H 2022; Present safety data from the Phase 1b combination trial with palbociclib - 2H 2022; Initiate two Phase 3 trials in patients with metastatic breast cancer - 2H 2022; Initiate a Phase 1b combination trial with cyclin dependent kinase inhibitors or other targeted therapies - 2H 2022; Initiate a Phase 1b combination trial with everolimus - 2H 2022; Initiate a Phase 2 neoadjuvant trial in patients with early breast cancer - 2H 2022. Bavdegalutamide: Discuss the potential accelerated approval path with the Food and Drug Administration - Q2 2022; Finalize partnership for a companion diagnostic - Q2 2022; Initiate a pivotal trial in mCRPC for patients with AR T878/H875 tumor mutations - 2H 2022. ARV-766: Share Phase 1 dose escalation data in mCRPC- 2H 2022; and Initiate Phase 2 expansion trial in mCRPC - 2H 2022.

07:15 EDT Karyopharm issues 2022 outlook - Based on its current operating plans, Karyopharm reaffirms the following for full year 2022: XPOVIO net product revenue to be in the range of $135 million to $145 million. Non-GAAP R&D and SG&A expenses, excluding stock-based compensation expense, for the year ending December 31, 2022, to be in the range of $265 million to $280 million. Karyopharm has not reconciled the full year 2022 outlook for non-GAAP R&D and SG&A expenses to full year 2022 outlook for GAAP R&D and SG&A expenses because Karyopharm cannot reliably predict without unreasonable efforts the timing or amount of the factors that substantially contribute to the projection of stock compensation expense, which is excluded from the full year 2022 outlook for non-GAAP R&D and SG&A expenses. The Company expects that its existing cash, cash equivalents and investments, and the revenue it expects to generate from XPOVIO product sales, as well as revenue generated from its license agreements, will be sufficient to fund its planned operations into early 2024.

07:13 EDT Bally's terminates consideration of Standard General's proposal - Bally's announced that a special committee of its board of directors has terminated consideration of Standard General's proposal to acquire all of the outstanding shares of Bally's that it did not already own. Bally's simultaneously announced that its board of directors determined that Bally's should pursue initiating a cash tender offer for its shares. It is anticipated that the tender offer will involve $300M-$500M, and will be structured in a Dutch auction format. The commencement of the offer is subject to, among other things, obtaining necessary financing and final approval by Bally's board. Lee Fenton, Bally's CEO, said, "The company has very substantial opportunities before it, including the integration of the Gamesys acquisition, the build-out of Bally's North American interactive business and the continued strategic expansion of our land-based footprint in the U.S. With these opportunities in front of us, we have great confidence in the future as we move forward."

07:11 EDT Zentalis expects cash to fund requirements into 1Q24 - As of March 31, 2022, Zentalis had cash, cash equivalents and marketable securities of $289.4 million. The Company believes that its existing cash, cash equivalents and marketable securities as of March 31, 2022, together with approximately $24.7 million of net proceeds from the April 2022 Pfizer equity investment, prioritization of the clinical development of ZN-c3 and ZN-d5, and budget reallocation, will be sufficient to fund its operating expenses and capital expenditures requirements into the first quarter of 2024.

07:07 EDT Aveo Pharmaceuticals expects cash to fund operations for more than 12 months - AVEO believes that its $79.0 million in cash, cash equivalents and marketable securities as of March 31, 2022, along with expected net product revenues from the sales of FOTIVDA in the United States, will enable AVEO to maintain its current operations for a period of more than 12 months from the date of filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022.

07:05 EDT Autolus Therapeutics expects cash to provide cash runway into 2024 - Cash at March 31, 2022, totaled $268.6 million, as compared to $310.3 million at December 31, 2021. Autolus estimates that its current cash on hand and anticipated milestone payments from Blackstone extends the Company's runway into 2024.

07:05 EDT Autolus Therapeutics announces anticipated milestones - Key Anticipated Clinical Milestones: Initial clinical data from the FELIX Phase 2 trial in H2 2022 and full data in H1 2023; Updated Phase 1 data from the ALLCAR19 extension trial in patients with r/r B-NHL and CLL presented as a poster at the EHA Congress in June 2022; Updates on the obe-cel Phase 1 CAROUSEL trial in Primary CNS Lymphoma presented as a poster at the EHA Congress in June 2022; Initial clinical data from the AUTO1/22 CARPALL extension trial in pediatric ALL presented as an oral presentation at the EHA Congress in June 2022, with longer follow up in H2 2022; Initial clinical data from AUTO4 LibraT1 Phase 1 trial in TRBC1+ Peripheral TCL presented as an oral presentation at the EHA Congress in June 2022; AUTO6NG Phase 1 clinical trial in neuroblastoma expected to start in H2 2022. Expect first data in H2 2023; AUTO8 Phase 1 clinical trial in patients with multiple myeloma has started, expect first data in H2 2023.

06:58 EDT Wayfair CFO Michael Fleisher to retire, Kate Gulliver to succeed - Wayfair announced the upcoming retirement of Michael Fleisher, CFO, and the planned appointment of Kate Gulliver to the role of CFO and Chief Administrative Officer in November. Gulliver is being named incoming CFO on May 5 and will formally assume the CFO and CAO role in November. At that point, Fleisher will stay on for a transition period until his retirement on January 15, 2023.

06:47 EDT Denbury backs previous 2022 production guidance - Anticipates full-year 2022 oil & gas capital expenditures, lease operating expense, and G&A to be in the upper half to upper end of their respective annual ranges for the year. The Company's full-year 2022 production guidance range is unchanged. For Q2, the company anticipates sales volumes to be slightly lower than the first quarter of 2022 as a result of the timing of workover and development activities, with production volumes anticipated to grow through the second half of 2022. LOE per BOE is anticipated to increase in Q2 primarily as a result of higher commodity prices and increased seasonal workover operations. Oil & gas development capital expenditures are anticipated to increase in the second quarter over the first quarter, driven by continued activity at CCA, including purchase of equipment for the EOR recycle facilities, as well as additional drilling and development activities across the company's Rocky Mountain and Gulf Coast regions.

06:34 EDT WestRock announces additional 25M share repurchase program

06:27 EDT California Resources raises 2022 production view to 91,000-94,000 BOEPD - Increasing its 2022 capital program to $340M-$385M from $330M-$375M. Raising free cash flow and adjusted EBITDAX guidance by 17% and 11% at the midpoint, respectively, to $330M-$410M and $860M-$960M.

06:26 EDT AstraZeneca's Enhertu approved in U.S. in HER2-positive breast cancer - The company states: "Daiichi Sankyo (DSNKY) and AstraZeneca's (AZN) Enhertu has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo. The approval by the FDA was based on positive results from the DESTINY-Breast03 Phase III trial that showed Enhertu reduced the risk of disease progression or death by 72% versus trastuzumab emtansine in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane." Reference Link

06:23 EDT AstraZeneca's Farxiga met primary endpoint in DELIVER Phase III trial - The company states: "The safety and tolerability profile of Farxiga in the DELIVER Phase III trial were consistent with the well-established safety profile of the medicine. The full DELIVER Phase III trial results will be submitted for presentation at a forthcoming medical meeting and regulatory submissions will be made in the coming months. High-level results from the DELIVER Phase III trial showed AstraZeneca's Farxiga reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular death or worsening heart failure. The trial was conducted in patients with HF with mildly reduced or preserved ejection fraction. The safety and tolerability profile of Farxiga in the DELIVER Phase III trial were consistent with the well-established safety profile of the medicine. The full DELIVER Phase III trial results will be submitted for presentation at a forthcoming medical meeting and regulatory submissions will be made in the coming months." Reference Link

06:21 EDT Li-Cycle, Glencore announce global strategic partnership - Li-Cycle announced a strategic partnership with Glencore, a provider of primary metals for the production of EV batteries. The strategic partnership will better serve the EV battery supply chain by providing customers with an integrated approach for their primary and recycled metal needs. Li-Cycle and Glencore have executed a global feedstock supply agreement under which Glencore will supply all types of manufacturing scrap and end-of-life lithium-ion batteries to Li-Cycle. Li-Cycle and Glencore have also entered into a non-binding Term Sheet for global, long-term strategic contracts, which would complement Li-Cycle's existing off-take and marketing agreements. Upon execution of the commercial agreements, Glencore will make a $200M investment in Li-Cycle and Glencore will have the right to nominate one board member to the Li-Cycle board. Li-Cycle has agreed to nominate Kunal Sinha, Glencore's Head of Recycling, to the Li-Cycle Board of Directors.

06:21 EDT AstraZeneca's Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial - The company states: "Positive high-level results from the open-label Phase III CHAMPION-NMOSD trial showed that Ultomiris achieved a statistically significant and clinically meaningful reduction in the risk of relapse in adults with anti-aquaporin-4 antibody-positive (Ab+) neuromyelitis optica spectrum disorder compared to the external placebo arm from the pivotal Soliris PREVENT clinical trial. Ultomiris, the first and only long-acting C5 complement inhibitor, met the primary endpoint of time to first on-trial relapse, as confirmed by an independent adjudication committee. Notably, no relapse was observed in 58 patients over a median treatment duration of 73 weeks. NMOSD is a rare and devastating autoimmune disease that affects the central nervous system, including the spine and optic nerves. Most people living with NMOSD often experience unpredictable relapses, a new onset of neurologic symptoms or worsening of existing neurologic symptoms, also referred to as attacks, which tend to be severe and recurrent and may result in permanent disability." Reference Link

06:18 EDT AB InBev sees FY22 EBITDA in line with 4%-8% medium-term outlook - The company said: "We expect our EBITDA to grow in-line with our medium-term outlook of between 4-8% and our revenue to grow ahead of EBITDA from a healthy combination of volume and price. The outlook for FY22 reflects our current assessment of the scale and magnitude of the COVID-19 pandemic, which is subject to change as we continue to monitor ongoing developments. We expect the normalized ETR in FY22 to be in the range of 28% to 30%, excluding any gains and losses relating to the hedging of our share-based payment programs. The ETR outlook does not consider the impact of potential future changes in legislation. We expect net capital expenditure of between 4.5 and 5.0 billion USD in FY22."

06:14 EDT TripAdvisor sees Q2 revenue in low to mid 90s as a percent of 2019 - Consensus is $362.24M. Sees consolidated adjusted EBITDA margin of approximately 20% of revenue.

06:12 EDT Airbus sees 720 commercial aircraft deliveries in 2022, EBIT adjusted EUR 5.5B - The company said, "The guidance issued in February 2022 remains unchanged. As the basis for its 2022 guidance, the Company assumes no further disruptions to the world economy, air traffic, the Company's internal operations, and its ability to deliver products and services. The Company's 2022 guidance is before M&A. On that basis, the Company targets to achieve in 2022 around: 720 commercial aircraft deliveries; EBIT Adjusted of EUR 5.5B; Free Cash Flow before M&A and Customer Financing of EUR 3.5B."

06:11 EDT Regis names Matthew Doctor as CEO - Regis (RGS) has appointed Matthew Doctor as the company's President and CEO and will join the company's Board of Directors. Matt has been serving as the company's Interim CEO since December 2021 and previously was Executive Vice President and Chief Strategy Officer. Prior to joining the company in February 2021, he was a Partner of Kava Restaurants LLC, a Tim Horton's franchisee. Prior to Kava, Matt held several roles at Restaurant Brands International (QSR), including Head of Global Development and Franchisee Performance for the Burger King brand. Matt started his career in investment banking with J.P. Morgan (JPM).

06:10 EDT Airbus sees A320 Family monthly production of 65 aircraft by summer 2023 - The company said, "Commercial aircraft production for the A320 Family is progressing towards a monthly rate of 65 aircraft by summer 2023, in a complex environment. Following an analysis of global customer demand as well as an assessment of the industrial ecosystem's readiness, the Company is now working with its suppliers and partners to enable monthly production rates of 75 in 2025. This production increase will benefit the entire global industrial value chain. Airbus will meet the higher production rates by increasing capacity at its existing industrial sites and growing the industrial footprint in Mobile, US, while investing to ensure that all commercial aircraft assembly sites are A321-capable."

06:05 EDT Ball Corp.positioned to return $1.75B to shareholders, deploy $1.8B in CapEx - "The company is well-positioned for near-term and long-term growth, cost/price recovery and accelerating return of value to shareholders despite our recent decision to leave Russia. Over our 142-year history, we have successfully navigated economic and geopolitical volatility on many occasions. Our company's resiliency, financial strength and recession resistant business portfolio continues to provide both stability and sustainable growth prospects for our stakeholders. Powered by our ownership mindset, EVA discipline, cash from operations and long-term contracts with global strategic partners, we look forward to growing earnings and returning significant value to shareholders through share repurchases and dividends in 2022 and beyond," said Scott C. Morrison, executive vice president and CFO.

05:57 EDT PureTech Health announces $50M share repurchase program - PureTech Health announced that its board of directors has approved a share buyback program in respect of its ordinary shares of one pence each up to a maximum consideration of $50M. The share buyback program will be limited to the lower of $50M or 28,589,875 ordinary shares, in line with the general authority to repurchase shares, which was granted by shareholders at the most recent annual general meeting held on May 27, 2021, and it will be executed via open market purchases in accordance with applicable regulations, including those related to daily volume and price limitations. Further details of the share buyback program will follow.

05:49 EDT Morgan Stanley warns of civil liability over block trading claims in filing - In a regulatory filing, Morgan Stanley warned it faced potential civil liability stemming from allegations that the Wall Street bank caused share prices to fall before it executed the sale of large portions of stock. Morgan Stanley said in its report that it faced potential civil liability from "claims that have been or may be asserted by block transaction participants or others" who may argue they were "harmed or disadvantaged" because of, among other things, a share price decline allegedly caused by the bank.

05:44 EDT Shell commences second tranche of $8.5B share buyback program - Shell announced the commencement of trading in the second tranche of its $8.5B share buyback program previously announced on February 3. The company completed the first tranche of this share buyback program on May 4. In aggregate, between February 3 and May 4, the company repurchased 148,200,897 ordinary shares for an aggregate consideration of $4B. It is intended that, subject to market conditions, the second tranche of this buyback program will be completed by the company's Q2 results, which are scheduled for July 28. In the second tranche, the company has entered into an irrevocable, non-discretionary arrangement with a broker to enable the purchase of ordinary shares for a period up to and including July 22. The aggregate maximum consideration for the purchase of ordinary shares under the second tranche is $4.5B. The purpose of the second tranche is to reduce the issued share capital of the company. All shares repurchased as part of the second tranche will be cancelled. The maximum number of ordinary shares which may be purchased by the company under the second tranche is 473,893,931, which is the maximum pursuant to the authority granted by shareholders at the company's 2021 Annual General Meeting, less the number of ordinary shares repurchased by the company pursuant to the share buyback programs announced on July 29, 2021, December 2, 2021 and February 3.

05:37 EDT Full Truck Alliance updates status under HFCAA - Full Truck Alliance updates its status under the Holding Foreign Companies Accountable Act, or HFCAA. The Company was provisionally named by the United States Securities and Exchange Commission as a Commission-Identified Issuer on May 4, following the company's filing of the annual report on Form 20-F for the fiscal year ended December 31, 2021 with the SEC on April 25. The company understands that this identification under the HFCAA and its implementation rules issued thereunder indicates that the SEC determines that the company used a registered public accounting firm whose working paper cannot be inspected or investigated completely by the Public Company Accounting Oversight Board of the United States, or PCAOB, to issue the audit opinion for its financial statements for the fiscal year ended December 31, 2021. In accordance with the HFCAA, the SEC shall prohibit a company's securities from being traded on a national stock exchange or in the over-the-counter trading market in the United States if the company has been identified by the SEC for three consecutive years due to PCAOB's inability to inspect the auditor's working paper. The company has been actively exploring possible solutions to protect the interest of its shareholders. The company will continue to comply with applicable laws and regulations in both China and the United States.

05:35 EDT Google acquires MicroLED display maker Raxium - Rick Osterloh, SVP, Devices & Services at Google, said in a blog post on Wednesday that the company has acquired Raxium, "an innovator in single panel MicroLED display technologies. The team at Raxium has spent five years creating miniaturized, cost-effective and energy efficient high-resolution displays that have laid the foundation for future display technologies. Raxium's technical expertise in this area will play a key role as we continue to invest in our hardware efforts. Raxium is based in Fremont, California and will join Google's Devices & Services team. We're thrilled to have the team at Raxium on board to help further our goal of building helpful devices and services to improve people's daily lives." Reference Link

05:30 EDT Nio provides update on HFCAA status - Nio provided an update on its status under the Holding Foreign Companies Accountable Act, or HFCAA. Nio is aware that the company has been provisionally identified by the SEC under the HFCAA. The company understands such identification may result from its filing of the annual report on Form 20-F for the fiscal year ended December 31, 2021. Nio understands the SEC made such identification pursuant to the HFCAA and its implementation rules issued thereunder, and this indicates that the SEC determines that the company used an auditor whose working paper cannot be inspected or investigated completely by the PCAOB, to issue the audit opinion for its financial statements for the fiscal year ended December 31, 2021. In accordance with the HFCAA, if the SEC determines that the company filed an annual report containing an audit report issued by a registered public accounting firm that has not been subject to inspection for the PCAOB for three consecutive years beginning in 2021, the SEC shall prohibit the shares or American depositary shares of the company from being traded on a national securities exchange or in the over-the-counter trading market in the United States. Nio has been actively exploring possible solutions to protect the interest of its stakeholders. On March 10, the company completed a secondary listing of its Class A ordinary shares on the Main Board of the Hong Kong Stock Exchange under the stock code "9866." The Class A ordinary shares listed on the HKEX are fully fungible with the ADSs listed on the NYSE. Nio will continue to comply with applicable laws and regulations in both China and the United States, and strive to maintain its listing status on both the NYSE and the HKEX in compliance with applicable listing rules.

05:20 EDT Vista Outdoor reports Q4 sporting products sales $464M, up 56% - Reports Q4 outdoor products sales $345M, up 15%.

05:13 EDT Vista Outdoor to make Outdoor Products, Sporting Products segments public - Vista Outdoor announced that its board of directors has unanimously approved a plan to separate its Outdoor Products and Sporting Products segments into two independent, publicly-traded companies. The company expects to create these companies through a tax-free spin-off of its Outdoor Products segment to Vista Outdoor shareholders. Following the separation, the company's Outdoor Products segment will be a platform of outdoor brands including CamelBak, Bell, Giro, Camp Chef, Bushnell, Bushnell Golf, Foresight Sports, Stone Glacier and QuietKat. As an independent company, Sporting Products will continue to focus on ammunition categories through its renowned brands including Federal, Remington, CCI, Speer, Estate Cartridge and HEVI-Shot. Outdoor Products' capital allocation strategy will prioritize growth through the strategic acquisition of complementary outdoor businesses, as well as reinvestment in organic growth through new product development, marketing and expanded e-commerce and international sales. Outdoor Products will be led by Chris Metz as CEO and Sudhanshu Priyadarshi as CFO following completion of the separation. The other members of the Outdoor Products leadership team will be announced at a later date. Outdoor Products will be headquartered in Bozeman, Montana. Sporting Products' capital allocation strategy will prioritize using its cash flow for returning capital to shareholders. Jason Vanderbrink, who is currently president of Sporting Products, will be appointed CEO following completion of the separation. The other members of the Sporting Products leadership team will be announced at a later date. Sporting Products will continue to be headquartered in Anoka, Minnesota. Vista Outdoor anticipates that the transaction will be in the form of a distribution to its shareholders of 100% of the stock of Outdoor Products, which will become a new, independent publicly traded company. The distribution is intended to be tax-free to U.S. shareholders for U.S. federal income tax purposes. Vista Outdoor currently expects the transaction will be completed in calendar year 2023, subject to final approval by the company's board of directors, a Form 10 registration statement being declared effective by the U.S. Securities and Exchange Commission, regulatory approvals and satisfaction of other conditions. There can be no assurance regarding the ultimate timing of the proposed transaction or that the transaction will be completed.